Benzodioxole compound and medical application thereof

By designing benzodioxolone compounds with dual action mechanisms, as 5-HT reuptake inhibitors and 5-HT1A receptor agonists, the problems of slow onset and low efficacy of existing antidepressants have been solved, and the results of the achievement of the Fast and powerful antidepressant effects.

CN118930514APending Publication Date: 2024-11-12ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410981875.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing antidepressant drugs have a long time to onset and are inefficient, and cannot quickly and effectively improve the 5-HT level of synaptic clefts. In addition, classical drugs activate the 5-HT1A autoreceptor of the slit nucleus, resulting in negative feedback inhibition, affecting the efficacy.

Method used

Design a benzodioxolene compound with a dual mechanism of action, as a 5-HT reuptake inhibitor (SSRI) and 5-HT1A receptor agonist, directly acting on presynaptic and postsynaptic 5-HT1A receptor , promotes its desensitization and stimulates 5-HT-energic neurological function.

Benefits of technology

A rapid and powerful antidepressant effect was achieved, and the effect of treating depression was improved through dual mechanisms acting simultaneously on both presynaptic and postsynaptic 5-HT1A receptors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930514A_ABST
    Figure CN118930514A_ABST
Patent Text Reader

Abstract

The invention relates to a compound as shown in a formula I, pharmaceutically acceptable salt, an isotope labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a co-crystal of the compound, and also relates to a pharmaceutical composition containing the compound. The invention also relates to the use of said compounds for the preparation of a medicament for the treatment and / or prevention of a disease or condition in a subject, # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a benzodioxole compound and a structural derivative thereof, a pharmaceutically acceptable salt, an isotope-labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a cocrystal thereof, a pharmaceutical composition containing the compound, and an application of the compound in preparing a drug for treating and / or preventing a disease or condition in a subject. Background Art

[0002] Depression is a common and serious mental disorder that affects hundreds of millions of people worldwide. It not only has a serious impact on the patient's mental health, but can also lead to physical symptoms and a significant decline in social functioning. The main features of depression include persistent low mood, loss of interest or pleasure in daily activities, changes in appetite and weight, sleep disorders, fatigue, difficulty concentrating, feelings of helplessness, worthlessness, and in severe cases, suicidal thoughts or behaviors.

[0003] At present, the pathophysiological mechanism of depression has not been fully elucidated. Studies have shown that depression is mainly related to five neurotransmitters in the central nervous system: serotonin (5-HT), norepinephrine (NA), dopamine (DA), acetylcholine (Ach) and γ-aminobutyric acid (GABA). Existing effective drugs mainly work by regulating the levels of neurotransmitters in the synaptic cleft of nerve endings. The onset of action of commonly used antidepressants generally takes 2-4 weeks, and the effectiveness is only 50%-60%. This is because although classic antidepressants can increase the level of 5-HT in the synaptic cleft within a few hours, they also activate the 5-HT in the raphe nucleus. 1A The autoreceptors produce negative feedback inhibition, reducing the synthesis and release of 5-HT. After 2-4 weeks of administration, 5-HT 1A The autoreceptors are desensitized, expression is reduced, negative feedback inhibition is weakened, 5-HT neurons resume normal discharge, and activate postsynaptic 5-HT receptors, resulting in a significant increase in extracellular 5-HT. This also means that the antidepressant effect of the drug can only be produced after the autoreceptors are desensitized.

[0004] At present, multi-mechanism antidepressant drugs targeting 5-HT transporter and its receptor subtypes have shown their advantages in antidepressant efficacy. Among them, the representative drugs vilazodone and vortioxazine were approved by the FDA in 2011 and 2013, respectively, for the treatment of major depression in adults. 1A Antidepressants that have dual effects of agonist and 5-HT reuptake inhibitory effects not only act on presynaptic 5-HT 1A receptors, promoting their desensitization and directly stimulating the postsynaptic membrane 5-HT 1AIf the 5-HT receptors are activated and the 5-HT nerve function is promoted, it may have a strong and rapid antidepressant effect, and this concept is expected to represent the research and development direction of new antidepressant drugs. Summary of the invention

[0005] The present invention provides a benzodioxole compound, which has a dual mechanism of action in treating depression and can be used as a 5-HT reuptake inhibitor (SSRI) and a 5-HT 1A Receptor agonist, thus producing a good antidepressant effect.

[0006] The first aspect of the present invention provides a compound represented by formula I, a pharmaceutically acceptable salt, an isotope-labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a cocrystal thereof,

[0007]

[0008] in:

[0009] X is selected from C 1-6 Alkylene, -NH-, -O-(CH 2 ) m -, -C(=O)-, CH(OH)-, -CH 2 NH-,

[0010] CH 2 C(=O)-, -NHC(=O)-, -OC(=O)- and -CH=CHC(=O), wherein m is 0, 1, 2,

[0011] 3, 4, 5 or 6;

[0012] Y is N or CH;

[0013] R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Alkylamino;

[0014] n is 0, 1, 2, 3 or 4;

[0015] Ar 1 for Where R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-6Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Alkylamino.

[0016] In certain embodiments, the compound has a structure shown in Formula I-1, Formula I-2 or Formula I-3,

[0017]

[0018] Where X, Y, R 1 , n are defined as described in any embodiment of the present invention.

[0019] In certain embodiments, in Formula I, X is selected from 1-4 Alkylene, -NH-, -O-(CH 2 ) m -, -C(=O)-, CH(OH)-, -CH 2 NH-、CH 2 C(═O)—, —NHC(═O)—, —OC(═O)—, and —CH═CHC(═O), wherein m is 0, 1, 2, 3, or 4.

[0020] In certain embodiments, in Formula I, X is selected from C 1-4 Alkylene, -O-(CH 2 ) m - and -CH=CHC(=O), wherein m is 0, 1, 2, 3 or 4.

[0021] In certain embodiments, in Formula I, X is selected from -O-CH 2 -、-O-(CH 2 ) 2 -、-O-(CH 2 ) 3 -、-O-(CH 2 ) 4 -、-CH=CHC(=O)-、-CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-(CH 2 ) 4 -、-CH 2 CH 2 CH(CH 3 )-、-CH 2 CH(CH 3 )CH 2 - and -CH(CH 3 )CH 2 CH 2 -.

[0022] In certain embodiments, in Formula I, X is selected from -O-(CH 2 ) 4 -、-O-(CH 2 ) 2 -、-O-(CH 2 ) 3 -、-CH=CHC(=O)-、-CH 2 -、-CH 2 CH 2 CH(CH 3 )-、-(CH 2 ) 3 -、-(CH 2 ) 4 - and - (CH 2 ) 2 -.

[0023] In certain embodiments, R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Alkylamino.

[0024] In certain embodiments, R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl and C 1-4 Alkoxy.

[0025] In certain embodiments, R 1 Selected from H, D, F, Cl, Br, I, C 1-4 Alkyl and C 1-4 Alkoxy.

[0026] In certain embodiments, R 1 Selected from H, D, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, n-butoxy.

[0027] In certain embodiments, R 1 Selected from H, D, F, Cl, Br, I, methoxy, ethoxy, n-propoxy, n-butoxy.

[0028] In certain embodiments, R 1is selected from H, D, F, Cl, Br, I and methoxy.

[0029] In certain embodiments, R 1 is selected from H, F, Cl, Br, I and methoxy.

[0030] In certain embodiments, R 1 Selected from H, Cl and methoxy.

[0031] In certain embodiments, n in Formula I is 0, 1, 2 or 3.

[0032] In certain embodiments, n in Formula I is 0, 1 or 2.

[0033] In certain embodiments, n in Formula I is 0 or 1.

[0034] In certain embodiments, R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Alkylamino.

[0035] In certain embodiments, R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl and C 1-4 Alkoxy.

[0036] In certain embodiments, R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, C 1-4 Alkyl and C 1-4 Alkoxy.

[0037] In certain embodiments, R 2 , R 3 Each is independently selected from H, D, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, and n-butoxy.

[0038] In certain embodiments, R 2 , R 3Each is independently selected from H, D, F, Cl, Br, I, methoxy, ethoxy, n-propoxy, and n-butoxy.

[0039] In certain embodiments, R 2 , R 3 Each is independently selected from H, D, F, Cl, Br, I and methoxy.

[0040] In certain embodiments, R 2 , R 3 Each is independently selected from H, F, Cl, Br, I and methoxy.

[0041] In certain embodiments, R 2 , R 3 are each independently selected from H and methoxy.

[0042] In certain embodiments, R 2 For H, R 3 It is a methoxy group.

[0043] In certain embodiments, Ar in Formula I 1 for

[0044] In certain embodiments, the compound of formula I is selected from:

[0045]

[0046]

[0047]

[0048]

[0049]

[0050] The second aspect of the present invention provides a pharmaceutical composition comprising a compound as described in the first aspect of the present invention, a pharmaceutically acceptable salt, an isotope-labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a cocrystal thereof, and one or more pharmaceutically acceptable carriers and / or excipients.

[0051] The third aspect of the present invention provides the use of the compound of the first aspect of the present invention, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal or the pharmaceutical composition of the second aspect of the present invention in the preparation of a medicament for treating and / or preventing a disease or condition in a subject, wherein the disease or condition is related to 5-HT 1A Receptor and / or 5-HT transporter (SERT) related diseases.

[0052] In certain embodiments, the disease or condition is selected from cancer, pain, a neurological disease, an immune system disease, and any combination thereof.

[0053] In certain embodiments, the disease or condition is selected from hypertension, attention deficit / hyperactivity disorder (ADHD), pain, panic disorder, opioid withdrawal symptoms, benzodiazepines drug withdrawal symptoms, alcohol withdrawal symptoms, neurological disorders, and any combination thereof.

[0054] In certain embodiments, the neurological disease is selected from depression, bipolar disorder, anxiety, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), schizophrenia, generalized anxiety disorder, phobia, panic disorder, eating disorders, attention deficit hyperactivity disorder (ADHD), borderline personality disorder, dissociative identity disorder, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, cerebrovascular disease, cerebral palsy, neuropathic pain, chronic fatigue syndrome, sleep disorders, movement disorders, and any combination thereof.

[0055] The compounds, pharmaceutically acceptable salts, isotope-labeled compounds, racemates, enantiomers, solvates, hydrates, crystal forms or co-crystals of the present invention can be administered by appropriate routes such as oral, sublingual, rectal, parenteral, injection (intradermal, subcutaneous, intramuscular, intravenous, arterial injection), pulmonary, nasal, tongue, cheek, skin, mucosa, conjunctiva, topical administration or in the form of implants. The compounds, pharmaceutically acceptable salts, isotope-labeled compounds, racemates, enantiomers, solvates, hydrates, crystal forms or co-crystals of the present invention can be used as a single drug for treatment or in combination with other drugs for treatment; they can also be used for short-term treatment or long-term maintenance treatment; they can also be combined with non-drug treatment methods such as psychotherapy, cognitive behavioral therapy, psychoanalytic therapy, family therapy, group therapy, etc. for treatment.

[0056] The compound of formula I of the present invention, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal can be synthesized by known methods using commercially available raw materials. Exemplary preparation methods of the compound of formula I, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal can include (but are not limited to) the process described below. In the specific operation process, the steps in the method can be expanded or combined as needed.

[0057] The compounds of the present invention can be synthesized according to any one of the following methods A to G:

[0058] The method A comprises: a compound shown in chemical formula 1 undergoes Williamson ether synthesis reaction with a dihaloalkane to prepare an intermediate 3; and intermediate 3 reacts with a key intermediate 4 under the action of an acid binding agent to generate a target product 5.

[0059]

[0060] Where: m, n, Y, R 1 , AR 1 The definition of is as described in the present invention.

[0061] The method B comprises: compound 6 reacts with triethyl phosphoacetate in a Wittig-Horner reaction under strong alkaline conditions to obtain intermediate 7, intermediate 7 is hydrolyzed under alkaline conditions to obtain a sodium salt, and acid-amine condensation reaction is directly carried out with a key intermediate 4 under the action of a condensation agent without acidification to obtain a target compound 8.

[0062]

[0063] Where: n, Y, R 1 , AR 1 The definition of is as described in the present invention.

[0064] The method C includes the following different situations:

[0065] (1) In 1,2-dichloroethane solvent, raw material 6 was directly reductively aminized with key intermediate 4 in a one-pot reaction under the action of sodium triacetoxyborohydride (STAB-H) to obtain target compound 9.

[0066]

[0067] (2) The raw material 6 reacts with 1-triphenylphosphine-propyl-2-one to undergo a Wittig reaction to obtain the intermediate 10. Under the action of sodium triacetoxyborohydride (STAB-H), the intermediate 11 undergoes a reductive amination reaction with the key intermediate 4 to obtain the intermediate 11, and then the double bond is reduced by 10% Pd / C to obtain the target compound 12.

[0068]

[0069] (3) The raw material 6 undergoes a nucleophilic addition reaction with the Grignard reagent methylmagnesium bromide to generate the intermediate 13, which is then dehydrated under alkaline conditions to obtain the intermediate 15, which is then subjected to an anti-Markovnikov addition reaction to obtain the intermediate 16. After the intermediate 16 is substituted with a halogen, it reacts with the key intermediate 4 to obtain the target compound 18.

[0070]

[0071] (4) Intermediate 7 was reduced twice to obtain intermediate 20, which was then substituted with halogen and reacted with key intermediate 4 to obtain target compound 22.

[0072]

[0073] (5) The starting material 6 was subjected to hydroboration reduction and bromination reaction, and then reacted with allylmagnesium bromide to generate intermediate 25, which was then subjected to anti-Markovnikov addition reaction to obtain intermediate 26. Intermediate 26 was substituted with p-toluenesulfonyl and then reacted with key intermediate 4 to obtain the target compound 28.

[0074]

[0075] Where: n, Y, R 1 , AR 1 The definition of is as described in the present invention.

[0076] The method D comprises: reducing the raw material carboxylic acid 29 to generate alcohol 30, reacting the alcohol 30 with p-toluenesulfonyl chloride after chlorination to obtain intermediate 32, and then performing substitution reaction with key intermediate 4 to obtain target compound 33.

[0077]

[0078] Where: m = 1-5, n, Y, AR 1 The definition of is as described in the present invention.

[0079] The method E comprises: reacting intermediate 32 with diethyl malonate, obtaining intermediate 35 through Krapcho reaction, reacting intermediate 35 with p-toluenesulfonyl chloride after reduction to obtain intermediate 37, and then performing substitution reaction with key intermediate 4 to obtain target compound 38.

[0080]

[0081] Where: n, Y, AR 1 The definition is as described in the claims.

[0082] For the key intermediate 4 of the present invention, when Y is N or CH, n=1, AR 1 for

[0083] When the preparation process of the corresponding key intermediate 4 is any one of the following methods F to G.

[0084] The method F comprises: raw material M 1 Reaction with triphenylphosphine to prepare Lindler's reagent to obtain phosphine salt M 2 After and M 3The Wittig reaction occurs to obtain the intermediate M 4 , remove the -Boc protecting group to generate intermediate M 5 Finally, the double bond is reduced to obtain the key intermediate M 6 .

[0085]

[0086] The method G comprises: raw material M 1 Reaction with N-Boc-piperazine to generate intermediate M 7 , remove the -boc protecting group to generate the key intermediate M 8 .

[0087]

[0088] Definition of terms

[0089] The various terms and phrases used in the present invention have the general meanings known to those skilled in the art. Even so, the present invention still hopes to provide a more detailed description and explanation of these terms and phrases. If the terms and phrases mentioned are inconsistent with the known meanings, the meanings expressed in the present invention shall prevail. The following are the definitions of various terms used in the present invention, which apply to the terms used in the entire specification of this application, unless otherwise specified in specific circumstances.

[0090] In the present invention, when the name of the compound used is inconsistent with the chemical structural formula, the chemical structural formula shall prevail.

[0091] In the present invention, the term "subject" refers to a mammal, such as a primate mammal, such as a human.

[0092] In the present invention, the term "and / or" should be considered as a specific disclosure of each of two or more specified features or elements, as well as any combination of two or more features or elements. Therefore, the term "and / or" used in a phrase, such as "A and / or B" herein, is intended to include "A and B", "A or B", "A" (alone) and "B" (alone).

[0093] In the present invention, the term "C 1-6 "Alkyl" refers to a saturated straight or branched monovalent hydrocarbon group having 1 to 6 carbon atoms, preferably 1 to 4, 1 to 3 or 1 to 2 carbon atoms. 1-6Representative examples of “alkyl” include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl groups and the like.

[0094] In the present invention, the term "C 1-6 "Alkylamino" refers to a C 1-6 Alkyl substituted amino. 1-6 Typical examples of "alkylamino" include, but are not limited to, methylamino, ethylamino, propylamino, butylamino, pentylamino, hexylamino and the like.

[0095] In the present invention, the term "C 1-6 "Alkoxy" means a group C 1-6 Alkyl-O-. "C 1-6 Typical examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexyloxy, 1,2-dimethylbutoxy, and the like.

[0096] In the present invention, the term "deuterated C 1-6 "Alkyl" means a C 1-6 alkyl.

[0097] In the present invention, the term "C 1-6 "Alkylene" refers to a saturated straight or branched divalent hydrocarbon group having 1 to 6 carbon atoms, preferably 1 to 4, 1 to 3 or 1 to 2 carbon atoms. 1-6 Typical examples of "alkylene" include, but are not limited to, -CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-(CH 2 ) 4 -、-CH 2 CH 2 CH(CH 3 )-、-CH 2 CH(CH 3 )CH 2 - and -CH(CH 3 )CH 2 CH 2 -wait.

[0098] The compounds of the present invention may exist in tautomeric forms, and the present invention also encompasses such forms.

[0099] The present invention encompasses all possible crystalline forms or polymorphs of the compound, which may be a single polymorph or a mixture of more than one polymorph in any ratio.

[0100] The compounds of the present invention may exist in the form of solvates (e.g., hydrates), wherein the compounds of the present invention include a solvent as a structural element of the crystal lattice of the compound, such as water, methanol or ethanol. The amount of the solvent may exist in a stoichiometric or non-stoichiometric ratio.

[0101] In the present invention, the term "isotope-labeled compound" refers to a compound in which one or more atoms are replaced with atoms of the same atomic number but with an atomic mass or mass number different from the atomic mass or mass number predominant in nature. Examples of isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, hydrogen isotopes such as 2 H, 3 H; carbon isotopes such as 11 C, 13C and 14 C; chlorine isotopes such as 36 Cl; fluorine isotopes such as 18 F; iodine isotopes such as 123 I and 125 I; Nitrogen isotopes such as 13 N and 15 N; oxygen isotopes such as 15 Oh, 17 O and 18 O; and sulfur isotopes such as 35 S.

[0102] In the present invention, the term "pharmaceutically acceptable" or "pharmaceutically usable" which is used interchangeably therewith, for example, when describing a "pharmaceutically acceptable salt", means that the salt may not only refer to a synthetic substance that is physiologically acceptable to a subject, but also may refer to a synthetic substance that has pharmaceutical use value, such as a salt formed as an intermediate when performing chiral separation. Although the salt of this intermediate cannot be directly administered to a subject, the salt may play a role in obtaining the final product of the present invention.

[0103] The compound of formula I of the present invention may also be in the form of its salt, generally a salt formed with an organic or inorganic base or acid, preferably a pharmaceutically acceptable salt. The pharmaceutically acceptable salt of the compound of the present invention may be a salt formed with an inorganic acid, carboxylic acid or sulfonic acid, and particularly preferably a salt formed with, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, fumaric acid, acetic acid, propionic acid, succinic acid, glycolic acid, formic acid, lactic acid, maleic acid, tartaric acid, citric acid, pamoic acid, malonic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, fumaric acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, hydroxynaphthoic acid, hydroiodic acid, malic acid, tannic acid. Other acids, such as oxalic acid, although not pharmaceutically acceptable per se, may be used to prepare salts used as intermediates to obtain the compound of the present invention and its pharmaceutically acceptable salt.

[0104] In the present invention, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with a subject and an active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Pharmaceutically acceptable carriers and / or excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human albumin, buffer substances such as phosphates, glycerol, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon oxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, beeswax, and lanolin.

[0105] In the present invention, the term "pharmaceutical composition" may also refer to a "composition" which can be used to achieve treatment and / or prevention of the diseases or disorders described in the present invention in a subject, especially a mammal.

[0106] In the present invention, the term "treatment" aims to alleviate, mitigate, improve or eliminate the disease state or condition. If the subject receives a therapeutic amount of the compound, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal according to the method described herein, and one or more signs and symptoms of the subject show an observable and / or detectable reduction or improvement, the subject is successfully "treated". It should also be understood that the treatment of the disease state or condition includes not only complete treatment, but also failure to achieve complete treatment, but achieving some biological or medically relevant results.

[0107] In the present invention, the term "prevention" aims to avoid, reduce, stop or delay the occurrence of a disease or disease-related symptoms, and such disease or disease-related symptoms have not yet appeared before the administration of the relevant drug. "Prevention" does not require completely stopping the occurrence of a disease or disease-related symptoms. For example, after the administration of the relevant drug, the risk of a subject developing a specific disease or disease-related symptom can be reduced, or the severity of the related symptoms that appear later can be reduced, which can be considered as "preventing" the occurrence or development of the disease.

[0108] The compounds of the present invention as active ingredients may have systemic and / or local effects and can therefore be administered by a suitable route, such as oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival, topical administration or in the form of an implant.

[0109] The compounds of the present invention can also be administered as active ingredients in administration forms suitable for these administration routes.

[0110] Suitable for oral administration are known administration forms which deliver the active ingredient rapidly and / or in a modified manner, such as tablets (uncoated or coated, such as tablets with enteric coating or film coating), capsules, dragees, granules, pellets, powders, emulsions, suspensions and aerosols.

[0111] With parenteral administration it is possible to avoid the absorption step (intravenous, intraarterial, intracardiac, intraspinal or intralumbar administration) or to include absorption (intramuscular, subcutaneous, intradermal, transdermal or intraperitoneal administration). Administration forms suitable for parenteral administration include preparations in the form of solutions, suspensions, emulsions, lyophilizates and sterile powders for injection and infusion.

[0112] Suitable other routes of administration include, for example, drugs for inhalation (particularly powder inhalation, spray), nasal drops / solutions, sprays; tablets or capsules for tongue, sublingual or buccal administration, suppositories, preparations for ears and eyes, vaginal capsules, aqueous suspensions (lotions, shaken mixtures), lipophilic suspensions, ointments, creams, emulsions, pastes, dusting powders or implants, such as stents.

[0113] The compounds according to the invention can be converted into the stated administration forms by known methods.

[0114] The compound of the present invention or the pharmaceutical composition or combination drug containing it can be administered in a unit dosage form. The pharmaceutical composition or combination drug can contain 0.01 mg to 1000 mg of the compound of the present invention, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal.

[0115] It must be recognized that the optimal dosage and interval of the compounds of the present invention are determined by the properties of the compounds and external conditions such as the form, route and site of administration and the specific mammals to be treated, and this optimal dosage can be determined by conventional techniques. It must also be recognized that the optimal course of treatment, i.e., the daily dosage of the compound within a specified time, can be determined by methods known in the art.

[0116] The actual dosage level of each active ingredient in the pharmaceutical composition and combination of the present invention can be changed so that the amount of active compound obtained can effectively obtain the desired therapeutic response for a specific patient, composition and administration method. The dosage level must be selected based on the activity of the specific compound, the route of administration, the severity of the condition to be treated, and the condition and previous medical history of the patient to be treated. However, it is common practice in the art to start the dosage of the compound from the level required to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained. In general, the dosage of the compound of the present invention for mammals, especially humans, can be between 0.001-1000 mg / kg body weight / day.

[0117] Beneficial Effects

[0118] The compounds provided by the present invention have both 5-HT 1A The dual effects of receptor stimuli and 5-HT reuptake inhibition are: on the one hand, it acts on presynaptic 5-HT 1A On the other hand, it directly stimulates the 5-HT receptors on the postsynaptic membrane, promoting 5-HT nerve function, effectively producing a strong and rapid antidepressant effect. DETAILED DESCRIPTION

[0119] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0120] Since the starting materials for synthesizing benzodioxole compounds are mostly Class I hazardous chemicals that are easily precursors to narcotics, such as 3,4-methylenedioxyphenyl-2-propanone (CAS: 4676-39-5), piperonal (CAS: 120-57-0), safrole (CAS: 94-59-7), sassafras oil (CAS: 8006-80-2), isosafrole (CAS: 120-58-1), etc., the embodiments provided in the present invention can provide a feasible reference for synthesizing such benzodioxole compounds.

[0121] Example 1: Synthesis of 1-(4-(Benzo[d][1,3]dioxol-4-hydroxy)butyl)-4-phenylpiperazine (LY-1-27)

[0122]

[0123] [1-1] Synthesis of 4-(4-chlorobutoxy)benzo[d][1,3]dioxazole (Intermediate 1)

[0124] Weigh 2.76g (20mmol) of benzo[d][1,3]dioxol-4-ol and 3.31g (24mmol) of anhydrous potassium carbonate, place in a 100mL round-bottom flask, add 40mL of acetone as solvent, and stir to dissolve the mixture. Add 3.17g (22mmol) of 1-bromo-4-chlorobutane dropwise, and stir under reflux for 8 hours. After TLC detection shows that the reaction is no longer proceeding, the reaction solution is cooled to room temperature, solid potassium carbonate is filtered out, and the filter residue is washed with a small amount of acetone. The filtrate is concentrated, the residue is dissolved in ethyl acetate, and the organic layer is washed with water and saturated brine in turn. The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated, separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1), and dried in vacuo to obtain 4.1g of intermediate 1, which is a white solid with a yield of 89.7%. ESI-MS m / z: 229.06 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)6.80-6.73(m,1H),6.62(dd,J=8.5,1.0Hz,1H),6.58(dd,J=7.8,1.0Hz,1H),5.96(s,2H), 4.08(t,J=6.1Hz,2H),3.70(t,J=6.4Hz,2H),1.86(tdd,J=7.6,6.1,3.3Hz,2H),1.84-1.78(m,2H).

[0125] [1-2] Synthesis of 1-(4-(Benzo[d][1,3]diol-4-hydroxy)butyl)-4-phenylpiperazine (LY-1-27)

[0126] 2g of intermediate 1 (8.77mmol), 1.62g (10mmol) of N-phenylpiperazine and 2.07g (15mmol) of anhydrous potassium carbonate were added to a 100mL round-bottom flask. 50mL of acetonitrile was added to dissolve the solid, and the mixture was heated, stirred and refluxed for 8 hours. After the reaction was completed, the mixture was cooled to room temperature, the inorganic salts were filtered out, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, the acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:1). Drying under vacuum gave 2.11g of light yellow powdered solid compound LY-1-27 with a yield of 68.1%. ESI-MS m / z: 355.19 [M+H] +1 H; NMR (600MHz, DMSO-d 6 )δ(ppm)7.23-7.17(m,2H),6.83-6.74(m,2H),6.63(dd,J=8.5,1.0Hz,1H),6.57(dd,J=7.9,1.0Hz,1H),5.96(s,2H),4 .08(t,J=6.4Hz,2H),3.31(s,4H),3.19-3.01(m,4H),2.39(s,2H),1.73(dq,J=8.4,6.5Hz,2H),1.61(p,J=7.6Hz,2H).

[0127] Example 2: Synthesis of 2-(4-(4-(benzo[d][1,3]dioxol-4-hydroxy)butyl)piperazin-1-yl)pyrimidine (LY-1-28)

[0128] Referring to the method of compound LY-1-27 in Example 1, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine in step [1-2] to prepare compound LY-1-28, and 1.79 g of white solid was obtained with a yield of 57.4%. ESI-MS m / z: 357.18 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)8.35(d,J=4.7Hz,2H),6.78(t,J=8.1Hz,1H),6.66-6.59(m,2H),6.57(d,J=7.8Hz,1H),5.96(s,2H),4.08(t ,J=6.5Hz,2H),3.70(s,4H),3.32(s,2H),2.39(d,J=22.7Hz,4H),1.73(dq,J=8.5,6.5Hz,2H),1.60(p,J=7.4Hz,2H).

[0129] Example 3: Synthesis of 1-(2-(Benzo[d][1,3]dioxol-4-hydroxy)ethyl)-4-phenylpiperazine (LY-1-37)

[0130] [3-1] Synthesis of 4-(2-chloroethoxy)benzo[d][1,3]dioxazole (Intermediate 3)

[0131] Referring to the method of Intermediate 1 in Example 1, 1-bromo-2-chloroethane was used to replace 1-bromo-4-chlorobutane in step [1-1] to prepare Intermediate 3, and 3.24 g of white flaky solid was obtained with a yield of 81.0%. ESI-MS m / z: 201.02 [M+H] + ; 1 HNMR (600 MHz, DMSO-d 6 )δ(ppm)6.83-6.76(m,1H),6.62(ddd,J=12.5,8.2,1.0Hz,2H),5.99(s,2H),4.35-4.30(m,2H),3.99-3.85(m,2H).

[0132] [3-2] Synthesis of 2-(4-(2-(Benzo[d][1,3]dioxol-4-hydroxy)ethyl)-4-phenylpiperazine (LY-1-37)

[0133] Referring to the method of LY-1-27 in Example 1, intermediate 1 was replaced with intermediate 3 to prepare compound LY-1-37, and 1.23 g of white solid was obtained with a yield of 67.6%. ESI-MS m / z: 327.16 [M+H] + ; 1 HNMR (600 MHz, DMSO-d 6 )δ(ppm)7.22-7.18(m,2H),6.93(d,J=8.2Hz,2H),6.77(dt,J=9.3,7.7Hz,2H),6.66(d,J=8.4Hz,1H),6.58( d,J=7.8Hz,1H),5.97(s,2H),4.20(t,J=5.7Hz,2H),3.12(t,J=5.0Hz,4H),2.81-2.70(m,2H),2.64(s,4H).

[0134] Example 4: Synthesis of 2-(4-(2-(Benzo[d][1,3]dioxol-4-hydroxy)ethyl)piperazin-1-yl)pyrimidine (LY-1-38)

[0135] Referring to the method of LY-1-27 in Example 1, intermediate 1 was replaced by intermediate 3, and N-phenylpiperazine in step [1-2] was replaced by 2-(piperazin-1-yl)pyrimidine to prepare compound LY-1-38, and 1.13 g of white solid was obtained with a yield of 61.3%. ESI-MS m / z: 329.15 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)8.35(d,J=4.8Hz,2H),6.78(t,J=8.2Hz,1H),6.70-6.60(m,2H),6.58(d,J=7 .8Hz,1H),5.97(s,2H),4.20(t,J=6.0Hz,2H),3.72(s,4H),3.30(s,4H),2.72(s,2H).

[0136] Example 5: Synthesis of 1-(3-(Benzo[d][1,3]dioxol-4-hydroxy)propyl)-4-phenylpiperazine (LY-1-44)

[0137] [5-1] Synthesis of 4-(3-chloropropoxy)benzo[d][1,3]dioxazole (Intermediate 5)

[0138] Referring to the method of Intermediate 1 in Example 1, 1-bromo-3-chloropropane was used to replace 1-bromo-4-chlorobutane in step [1-1] to prepare Intermediate 5, and 3.80 g of colorless oily liquid was obtained with a yield of 89.0%. ESI-MS m / z: 215.04 [M+H] + ; 1 HNMR (600 MHz, DMSO-d 6 )δ(ppm)6.80(d,J=8.5Hz,1H),6.63(d,J=2.4Hz,1H),6.38(dd,J=8.4,2.5Hz,1H) ,5.96(s,2H),4.01(t,J=6.0Hz,2H),3.77(t,J=6.5Hz,2H),2.12(p,J=6.2Hz,2H).

[0139] [5-2] Synthesis of 1-(3-(Benzo[d][1,3]dioxol-4-hydroxy)propyl)-4-phenylpiperazine (LY-1-44)

[0140] Referring to the method of LY-1-27 in Example 1, intermediate 5 was used to replace intermediate 1 to prepare compound LY-1-44, and 0.86 g of white solid was obtained with a yield of 58.89%. ESI-MS m / z: 341.18 [M+H] + ; 1H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.26-7.15(m,2H),6.93(d,J=8.1Hz,2H),6.83-6.72(m,2H),6.63(d,J=8.4Hz,1H),6.58(d,J=7.8Hz,1H) ,5.97(s,2H),4.11(t,J=6.4Hz,2H),3.36(s,4H),3.13(t,J=4.9Hz,4H),2.53-2.52(m,2H),1.90(p,J=6.8Hz,2H).

[0141] Example 6: Synthesis of 2-(4-(3-(Benzo[d][1,3]dioxetine-4-oxy)propyl)piperazin-1-yl)pyrimidine (LY-1-43)

[0142] Referring to the method of LY-1-27 in Example 1, intermediate 1 was replaced by intermediate 5, and N-phenylpiperazine in step [1-2] was replaced by 2-(piperazin-1-yl)pyrimidine to prepare compound LY-1-43, and 0.74 g of white solid was obtained with a yield of 50.64%. ESI-MS m / z: 343.17 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)8.35(d,J=4.7Hz,2H),6.81-6.76(m,1H),6.65-6.59(m,2H),6.58(dd,J=7.8,0.9Hz,1H),5.97(s, 2H), 4.11 (t, J = 6.3Hz, 2H), 3.82-3.62 (m, 4H), 3.32 (s, 2H), 2.44 (d, J = 11.9Hz, 4H), 1.89 (p, J = 6.6Hz, 2H).

[0143] Example 7: Synthesis of (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-19)

[0144]

[0145] [7-1] Synthesis of ethyl (E)-3-(7-methoxybenzo[d][1,3]dihydroxy-5-yl)acrylate (Intermediate 7-1)

[0146] Weigh 3.73 g (16.7 mmol) of triethyl phosphoacetate in a dry 100 mL three-necked flask and add 10 mL of anhydrous tetrahydrofuran to dissolve. Place the flask in an ice bath and cool to 0 ° C under nitrogen protection. Under a nitrogen atmosphere, slowly add 0.36 g of sodium hydride (15 mmol) to the reaction flask. Stir the mixture for 10 minutes to ensure that the sodium hydride is completely dissolved and the phosphonate salt is formed. Dissolve 2 g (11.1 mmol) of 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde in 10 mL of anhydrous THF to form a solution. Under a nitrogen atmosphere, slowly add the aldehyde solution to the reaction mixture dropwise while keeping the ice bath cool. After the addition is complete, continue to stir the reaction mixture in the ice bath for 30 minutes, then move to room temperature and continue stirring. After the reaction is complete, add water to terminate the reaction. Transfer the reaction mixture to a separatory funnel and extract the organic phase with dichloromethane 3 times, 20 mL each time. After combining the organic phases, dry them over anhydrous sodium sulfate. The drying agent was filtered and the solvent was dried to obtain a crude product. The crude product was dissolved in a small amount of dichloromethane and purified by silica gel column chromatography. The eluent was petroleum ether: ethyl acetate (4:1). The purified product was collected and dried to obtain intermediate 7-1, which was a white solid of 2.62 g with a yield of 94.37%. ESI-MS m / z: 251.08 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 7.55 (d, J = 15.9 Hz, 1H), 7.08 (s, 2H), 6.55 (d, J = 15. 9Hz,1H),6.05(s,2H),4.17(q,J=7.1Hz,2H),3.85(s,3H),1.25(t,J=7.1Hz,3H).

[0147] [7-2] Synthesis of (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-19)

[0148] 2.62 g of intermediate 7-1 (10.5 mmol) and 0.96 g of LiOH (40 mmol) in step [7-1] were added to 15 mL of MeOH:H 2O (32:1) mixed solvent, stirred at room temperature for 8h. The reaction mixture was concentrated in vacuo to remove the solvent, 50ml DMF was added to the residue to dissolve, and 4.56g (12mmol) 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) was added. The solution was stirred and activated at 0°C for 30 minutes, and then 2g (12mmol) 2-(piperazine-1-yl) was added. Stirring was continued at room temperature and the reaction was monitored by TLC until the reaction no longer proceeded. Water was added to terminate the reaction, the reaction mixture was transferred to a separatory funnel, and the organic phase was extracted with ethyl acetate 3 times, 20mL each time. After combining the organic phases, they were dried over anhydrous sodium sulfate and then concentrated in vacuo to obtain the crude product, which was then eluted with petroleum ether: ethyl acetate (1:1) by silica gel column chromatography to obtain the pure product to obtain compound LY-1-19, which was a white solid of 2.2g with a yield of 57.12%. ESI-MS m / z: 367.15 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)8.39(s,1H),7.51(d,J=15.3Hz,1H),7.28(d,J=15.4Hz,1H),7.26-7.20(m,1H),6.95(dd,J=7.7,1.2Hz,1H),6.88 (t,J=7.9Hz,1H),6.67(t,J=4.8Hz,1H),6.13(s,2H),3.82-3.77(m,3H),3.74(s,2H),3.67(s,2H),2.50(p,J=1.9Hz,4H).

[0149] Example 8: Synthesis of (E)-3-(Benzo[d][1,3]dioxol-4-yl)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-16)

[0150] [8-1] Synthesis of ethyl (E)-3-(benzo[d][1,3]dioxol-4-yl)acrylate (Intermediate 8-1)

[0151] Referring to the method of intermediate 7-1 in Example 7, benzo[d][1,3]dioxol-4-carboxaldehyde was used to replace 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde to prepare intermediate 8-1 to obtain 2.23 g of colorless white solid with a yield of 91.40%. ESI-MS m / z: 221.07 [M+H] +;1H NMR(600MHz,DMSO-d6)δ(ppm)7.57(d,J=16.1Hz,1H),7.15(dd,J=8.2,1.1Hz,1H),6.99(dd,J=7.7,1.1Hz,1 H), 6.89 (t, J = 7.9Hz, 1H), 6.63 (d, J = 16.1Hz, 1H), 6.15 (s, 2H), 4.19 (q, J = 7.1Hz, 2H), 1.26 (t, J = 7.1Hz, 3H).

[0152] [8-2] Synthesis of (E)-3-(Benzo[d][1,3]dioxol-4-yl)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-16)

[0153] Referring to the method of compound LY-1-19 in Example 7, intermediate 8-1 was used to replace intermediate 7-1 to prepare compound LY-1-16, and 1.59 g of white solid was obtained with a yield of 47.31%. ESI-MS m / z: 339.14 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)8.40(d,J=4.7Hz,2H),7.51(d,J=15.4Hz,1H),7.27(d,J=15.4Hz,1H),7.23(dd,J=8.1,1.2Hz,1H),6.95(dd,J= 7.8,1.1Hz,1H),6.88(t,J=7.8Hz,1H),6.67(t,J=4.7Hz,1H),6.13(s,2H),3.84-3.75(m,4H),3.73(s,2H),3.66(s,2H).

[0154] Example 9: Synthesis of (E)-3-(7-methoxybenzo[d][1,3]dioxol-5-yl)-1-(4-phenylpiperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-11)

[0155] Referring to the method of compound LY-1-19 in Example 7, 2-(piperazin-1-yl)pyrimidine was replaced with N-phenylpiperazine to prepare compound LY-1-11, and 2.3 g of white solid was obtained with a yield of 58.7%. ESI-MS m / z: 367.16 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.44(d,J=15.3Hz,1H),7.24(dd,J=8.6,7.1Hz,3H),7.15(d,J=1.4Hz,1H),7.04(d,J=1.4Hz,1H),7.01-6.97( m,2H),6.82(t,J=7.2Hz,1H),6.04(s,2H),3.87(s,3H),3.76-3.65(m,2H),3.15(d,J=12.2Hz,4H),1.44-1.12(m,2H).

[0156] Example 10: Synthesis of (E)-3-(Benzo[d][1,3]dioxol-4-yl)-1-(4-phenylpiperazin-1-yl)malonaldehyde-2-en-1-one (LY-1-15)

[0157] Referring to the method of compound LY-1-19 in Example 7, intermediate 8-1 was used to replace intermediate 7-1, and N-phenylpiperazine was used to replace 2-(piperazin-1-yl)pyrimidine to prepare compound LY-1-15, and 1.73 g of white solid was obtained with a yield of 51.6%. ESI-MS m / z: 337.15 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.49(d,J=15.4Hz,1H),7.28(d,J=15.4Hz,1H),7.26-7.20(m,3H),6.98(d,J=8.1Hz,2H),6.95(dd,J=7.8 ,1.1Hz,1H),6.88(t,J=7.8Hz,1H),6.82(t,J=7.2Hz,1H),6.14(s,2H),3.76(d,J=36.5Hz,4H),3.21-3.13(m,4H).

[0158] Example 11: Synthesis of 1-(Benzo[d][1,3]dihydroxy-4-ylmethyl)-4-phenylpiperazine (LY-2-39)

[0159]

[0160] Weigh 1g (6.67mmol) of benzo[d][1,3]dioxolane-4-carboxaldehyde, 1.3g (8mmol) of N-phenylpiperazine and 2.12g (10mmol) of sodium triacetoxyborohydride (STAB-H), add the reactants to a round-bottom flask in sequence and dissolve them with 1,2-dichloromethane (30mL), stir at room temperature, and detect the reaction to be complete by TLC. Post-treatment: Add an equal volume of water to the reaction solution, dry the organic layer with anhydrous sodium sulfate, filter, vacuum concentrate the filtrate, and prepare compound LY-2-39 by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain 1.34g of white solid with a yield of 67.9%. ESI-MS m / z: 296.15 [M+H] + ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)7.24-7.16(m,2H),6.93-6.89(m,2H),6.88-6.79(m,3H),6.7 6(t,J=7.3Hz,1H),6.00(s,2H),3.50(s,2H),3.11(t,J=4.8Hz,4H),2.54(d,J=6.3Hz,4H). 13 CNMR (151MHz, DMSO) δ (ppm) 151.49, 147.29, 146.36, 129.37, 123.64, 121.73, 119.43, 119.27, 115.87, 107.80, 101.04, 55.79, 52.93, 48.62.

[0161] Example 12: Synthesis of 2-(4-(Benzo[d][1,3]dihydroxy-4-ylmethyl)piperazin-1-yl)pyrimidine (LY-2-40)

[0162] Referring to the method of compound LY-2-39 in Example 11, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine to prepare compound LY-2-40, and 1.22 g of light yellow solid was obtained with a yield of 61.4%. ESI-MS m / z: 299.14 [M+H] + ; 1 HNMR(600MHz,DMSO-d6)δ(ppm)8.34(d,J=4.7Hz,2H),7.00-6.73(m,3H),6.61(t, J=4.7Hz,1H),6.00(s,2H),3.81-3.65(m,4H),3.49(s,2H),2.43(t,J=5.4Hz,4H). 13C NMR (151MHz, DMSO) δ (ppm) 161.65, 158.38, 147.30, 146.35, 123.60, 121.74, 119.37, 110.56, 107.81, 101.05, 55.86, 52.75, 43.70.

[0163] Example 13: Synthesis of 1-(7-methoxybenzo[d][1,3]dioxol-5-yl)methyl)-4-phenylpiperazine (LY-2-41)

[0164] Referring to the method of compound LY-2-39 in Example 11, 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde was used to replace benzo[d][1,3]dioxolane-4-carboxaldehyde to prepare compound LY-2-41, and 1.08 g of pale white solid was obtained with a yield of 49.73%. ESI-MS m / z: 327.16 [M+H] + ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)1H NMR (400MHz, DMSO) δ7.28-7.16(m,2H),6.93(d,J=8.2Hz,2H),6.78(t,J=7.2Hz,1H),6.70-6 .48(m,2H),5.99(s,2H),3.84(s,3H),3.45(s,2H),3.14(t,J=4.9Hz,4H),2.52-2.46(m,4H). 13 CNMR(151MHz,DMSO)δ(ppm)151.56,148.86,143.53,134.21,133.18,129.42,119.28,115.89,108.82,103.13,101.56,62.39,56.76,52.93,48.70.

[0165] Example 14: Synthesis of 2-(4-(7-methoxybenzo[d][1,3]dioxol-5-methyl)piperazin-1-yl)pyrimidine (LY-2-42)

[0166] Referring to the method of compound LY-2-39 in Example 11, benzo[d][1,3]dioxolane-5-carboxaldehyde was used to replace benzo[d][1,3]dioxolane-4-carboxaldehyde, and 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine to prepare compound LY-2-42, and 1.14 g of white solid was obtained with a yield of 52.3%. ESI-MS m / z: 329.15 [M+H] + ; 1H NMR (600MHz, DMSO-d6) δ (ppm) 8.35 (d, J = 4.8Hz, 2H), 6.70-6.53 (m, 3H), 5.98 ( s,2H),3.83(s,3H),3.74(t,J=5.2Hz,4H),3.43(s,2H),2.42(t,J=5.1Hz,4H). 13 C NMR (151MHz, DMSO) δ (ppm) 161.72, 158.39, 148.86, 143.53, 134.25, 133.05, 129.17, 110.57, 108.84, 103.12, 101.56, 62.41, 56.74, 52.75, 43.76.

[0167] Example 15: Synthesis of 1-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butan-2-yl)-4-phenylpiperazine (LY-2-8)

[0168]

[0169] [15-1] Synthesis of (E)-4-(7-methoxybenzo[d][1,3]dihydroxy-5-yl)but-3-en-2-one (Intermediate 15-1)

[0170] Under 0℃ ice bath condition, 1-triphenylphosphine-propyl-2-one (4g, 12mmol) was added to a tetrahydrofuran (50mL) solution of 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde (1.8g, 10mmol), and the resulting reaction mixture was stirred at room temperature for 20 hours. After the reaction, the reaction solvent was removed from the reaction mixture under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4:1) to prepare intermediate 15-1, and 2.0g of colorless oily liquid was obtained with a yield of 91.0%. ESI-MS m / z: 221.07[M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 7.53 (d, J = 16.2Hz, 1H), 7.10-7.03 (m, 2H), 6.73 (d, J = 16.2Hz, 1H), 6.06 (s, 2H), 3.87 (s, 3H), 2.30 (s, 3H).

[0171] [15-2] Synthesis of 1-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butan-2-yl)-4-phenylpiperazine (LY-2-8)

[0172] The intermediate 15-1 obtained in the previous step was added to a round-bottom flask, and 1.94g N-phenylpiperazine (12mmol) and 2.54g sodium triacetoxyborohydride (STAB-H) (12mmol) were added in sequence, and 1,2-dichloromethane (30mL) was added to dissolve, and stirred at room temperature. TLC was used to detect that the reaction was complete. An equal volume of water was added to the reaction solution, and the organic layer was obtained after separation. The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo. The intermediate 15-2 was prepared by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain 0.86g of white solid with a yield of 28.2%. Then, 10% Pd / C (1.0g, 1.0mmol) was added to the methanol solution (60mL) of the intermediate 15-2 obtained in the above reaction at room temperature, and the reaction system was filled with hydrogen. The reaction mixture was stirred under a hydrogen atmosphere for 23 hours. After the reaction, the reaction mixture was carefully filtered several times, dissolved with ethyl acetate, and the organic layer was washed with water and saturated brine in turn. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, dried in vacuo, and prepared by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain 0.67 g of a white solid with a yield of 71.4%. ESI-MS m / z: 371.20 [M+H] + ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)7.28-7.13(m,2H),6.98-6.88(m,2H),6.76(t,J=7.2Hz,1H),6.47(dd,J=10.0,1.4Hz,2H),5.95-5.88(m,2H),3.80 (s,3H),3.12(qt,J=11.4,5.7Hz,4H),2.64(dt,J=10.4,4.4Hz,2H),2.61 -2.51(m,4H),1.77(ddt,J=13.5,8.9,6.3Hz,1H),0.95(d,J=6.5Hz,3H).

[0173] Example 16: Synthesis of 1-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butan-2-yl)-4-phenylpiperazine (LY-2-7)

[0174] Referring to the method of compound LY-2-8 in Example 15, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine to prepare compound LY-2-7, and 0.66 g of light yellow solid was obtained with a yield of 69.5%. ESI-MS m / z: 329.15 [M+H] + ; 1H NMR (600MHz, DMSO-d6) δ (ppm) 8.34 (d, J = 4.7Hz, 2H), 6.60 (t, J = 4.7Hz, 1H), 6.49 (d, J = 1.4Hz, 1H), 6.47 (d, J = 1.4Hz, 1H), 5.95-5.90 (m, 2H), 3.80 ( s,3H),3.79-3.63(m,4H),3.32(s,2H),2.55(td,J=8.3,4.2Hz,4H),2.45 -2.35(m,2H),1.50(ddt,J=13.5,8.9,6.9Hz,1H),0.92(d,J=6.5Hz,3H).

[0175] Example 17: Synthesis of 1-(3-(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl)-4-phenylpiperazine (LY-2-9)

[0176]

[0177] [17-1] Synthesis of 6-(3-bromopropyl)-4-methoxybenzo[d][1,3]oxadiazole (Intermediate 17-3)

[0178] Weigh 2.5 g (10 mmol) of ethyl (E)-3-(7-methoxybenzo[d][1,3]dihydroxy-5-yl)acrylate (intermediate 7-1) obtained in Example 7, place it in a 100 ml two-necked bottle, add 45 ml of methanol solution, then add 10% Pd / C (1.0 g, 1.0 mmol) into the bottle, and fill the reaction system with hydrogen. Stir the reaction mixture under a hydrogen atmosphere, and monitor the reaction progress by TLC. After the reaction is completed, filter the reaction mixture, dissolve the filtrate with ethyl acetate, and wash the organic layer with water and saturated brine in turn. Dry the organic layer over anhydrous sodium sulfate, filter and concentrate under reduced pressure, and dry in vacuo to obtain 2.52 g of a crude product of intermediate 17-1 with a yield of 82.0%.

[0179] 0.6 g LiAlH 4 (15 mmol) was slowly added to the THF solution of the intermediate 17-1. The temperature was raised to room temperature and stirred for two hours. H 2 O (0.6 mL), 15% aqueous NaOH (0.6 mL) and H 2O (1.8mL) to quench the reaction. Filter the solution through diatomaceous earth. Pour the solution into ethyl acetate (30mL). Wash the organic layer with saturated brine. Dry the organic layer over anhydrous sodium sulfate, filter and concentrate under reduced pressure, then dissolve the resulting product with dichloromethane, slowly add 1.07g phosphorus tribromide (4mmol) at 0°C, and stir the reaction for 30 minutes before the reaction is complete. Carefully pour the reaction mixture into ice water to quench, transfer the mixture to a separatory funnel, and extract the organic phase with dichloromethane 3 times, 20mL each time. After combining the organic phases, dry them over anhydrous sodium sulfate. Filter the desiccant, concentrate the solvent under reduced pressure, and dry in vacuo to obtain 1.21g of intermediate 17-3 with a yield of 54.5%. ESI-MS m / z:273.01[M+H] + ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)6.40(dt,J=2.0,0.9Hz,1H),6.35(dt,J=2.0,0.9Hz,1H),5 .92(s,2H),3.84(s,3H),3.40(t,J=4.8Hz,2H),2.73(tt,J=7.3,0.9Hz,2H),2.10(s,2H).

[0180] [17-2] Synthesis of 61-(3-(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl)-4-phenylpiperazine (LY-2-9)

[0181] The obtained intermediate 17-3, 1.62g (10mmol) N-phenylpiperazine and 4.89g (15mmol) anhydrous cesium carbonate were added to a 100mL round-bottom flask. 50mL acetonitrile was added to dissolve the solid, and heated and stirred under reflux for 8 hours. After the reaction was completed, it was cooled to room temperature, filtered to remove inorganic salts, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1:1). Drying under vacuum gave compound LY-2-9 as a brown solid 1.04g, with a yield of 66.1%. ESI-MS m / z: 355.19 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.33-7.22(m,2H),6.98(d,J=8.1Hz,2H),6.83(t,J=7.2Hz,1H),6.57-6.50(m,2H),5.98(s,2H) ,3.86(s,3H),3.19(t,J=4.9Hz,4H),2.60(d,J=5.0Hz,6H),2.41(t,J=7.5Hz,2H),1.80(p,J=7.5Hz,2H).

[0182] Example 18: Synthesis of 2-(4-(3-(7-methoxybenzo[d][1,3]dioxol-5-yl)propyl)piperazin-1-yl)pyrimidine (LY-2-10)

[0183] Referring to the method of compound LY-2-9 in Example 17, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine to prepare compound LY-2-10, and 0.94 g of yellow powdery solid was obtained with a yield of 59.4%. ESI-MS m / z: 357.18 [M+H] + ; 1 HNMR(600MHz,DMSO-d6)δ(ppm)8.35(d,J=4.7Hz,2H),6.62(t,J=4.8Hz,1H),6.48(d,J=8.7Hz,2H),5 .93(s,2H),3.80(s,3H),3.71(s,4H),3.32(s,4H),2.41(s,2H),2.31(s,2H),1.74(q,J=7.5Hz,2H).

[0184] Example 19: Synthesis of 1-(3-(Benzo[d][1,3]dioxol-4-yl)propyl)-4-phenylpiperazine (LY-1-47)

[0185] Referring to the method of compound LY-2-9 in Example 17, benzo[d][1,3]dioxol-4-carboxaldehyde was used to replace 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde to prepare compound LY-1-47, and a white solid of 0.67 g was obtained with a yield of 46.2%. ESI-MS m / z: 325.18 [M+H] + ; 1H NMR(600MHz,DMSO-d6)δ(ppm)7.20(t,J=7.8Hz,2H),6.92(d,J=8.2Hz,2H),6.80-6.73(m,3H),6.72(dd,J=6.1 ,3.0Hz,1H),5.98(s,2H),3.31(s,4H),3.12(s,4H),2.57(t,J=7.7Hz,2H),2.36(s,2H),1.76(p,J=7.5Hz,2H). 13 CNMR(151MHz,DMSO)δ(ppm)151.50,147.09,145.54,129.39,123.70,122.90,121.88 ,119.24,115.79,106.84,100.80,57.64,53.14,48.60,40.64,40.52,27.22,26.72.

[0186] Example 20: Synthesis of 2-(4-(3-(Benzo[d][1,3]dioxol-4-yl)propyl)piperazin-1-yl)pyrimidine (LY-1-48)

[0187] Referring to the method of compound LY-2-9 in Example 17, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine, and benzo[d][1,3]dioxol-4-carboxaldehyde was used to replace 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde to prepare compound LY-1-48, and 0.63 g of white solid was obtained with a yield of 43.7%. ESI-MS m / z: 327.17 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 8.35 (d, J = 4.7Hz, 2H), 6.77-6.74 (m, 2H), 6.72 (dd, J = 6.1, 3.1Hz, 1H), 6.62 (t, J =4.7Hz,1H),5.98(s,2H),3.70(s,4H),2.58-2.55(m,2H),2.42(s,4H),1.86-1.73(m,2H),1.39-1.02(m,2H). 13 C NMR(151MHz,DMSO)δ(ppm)161.65,158.40,147.09,145.54,123.60,122.89,121 .89,110.61,106.86,100.81,57.61,52.90,43.65,40.63,40.51,29.49,27.13.

[0188] Example 21: Synthesis of 1-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butyl)-4-phenylpiperazine (LY-3-6)

[0189]

[0190] [21-1] Synthesis of 6-(but-3-en-1-yl)-4-methoxybenzo[d][1,3]diazole (Intermediate 21-3)

[0191] Weigh 1.8g 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde (10mmol), add 30mL methanol to dissolve the solid, slowly add 0.46g sodium borohydride (12mmol) under ice bath conditions, move to room temperature to continue the reaction, the reaction is completely completed after three hours, add water to quench at 0℃, remove methanol by rotary evaporation, and extract the organic phase with ethyl acetate 3 times, 20mL each time. After combining the organic phases, wash the organic layer with saturated brine, add anhydrous sodium sulfate to dry, filter and concentrate under reduced pressure, dissolve the resulting product with dichloromethane, slowly add 1.07g phosphorus tribromide (4mmol) at 0℃, stir and react for three hours until the reaction is complete. Pour the mixture carefully into ice water to quench, transfer the mixture to a separatory funnel, and extract the organic phase with dichloromethane 3 times, 20mL each time. After combining the organic phases, dry with anhydrous sodium sulfate. The desiccant was filtered, the solvent was concentrated under reduced pressure and dried in spun-on, and vacuum dried to obtain 1.84 g of intermediate 21-2 as a white solid powder with a yield of 75.3%.

[0192] The intermediate 21-2 obtained in the above process and 20 mL of anhydrous THF were added to a 100 mL three-necked flask equipped with a constant pressure dropping funnel. Under nitrogen protection, allyl magnesium bromide (15 mmol) was added dropwise in the constant pressure funnel at 0°C in an ice bath. The reaction was stirred at room temperature for 5 h, and then saturated NH 4 The mixture was quenched with Cl aqueous solution. The organic phase was extracted with dichloromethane 3 times, 20 mL each time. After the organic phases were combined, they were dried over anhydrous sodium sulfate, filtered through diatomaceous earth and concentrated under reduced pressure. They were separated by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1). Drying under vacuum gave 1.37 g of intermediate 21-3 as a colorless oily liquid with a yield of 88.2%. ESI-MS m / z: 207.09 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)6.46(dt,J=2.0,0.9Hz,1H),6.37(dt,J=2.0,0.9Hz,1H),5.93(s,2H),5.90-5.76(m,1H),5.13( ddt,J=16.1,2.3,1.3Hz,1H),4.98-4.92(m,1H),3.84(s,3H),2.67(td,J=7.7,1.0Hz,2H),2.33(m,2H).

[0193] [21-2] Synthesis of 1-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butyl)-4-phenylpiperazine (LY-3-6)

[0194] Under nitrogen, 1M BH 3 THF (8 mL, 8 mmol) was added to a THF (20 mL) solution of the intermediate 21-3 obtained in the above process. The mixture was cooled to 0°C. After stirring the reaction at 0°C for 30 minutes, the reaction mixture was heated to room temperature and continued to stir for 4 hours until the reaction was complete as monitored by TLC. 3M NaOH (10 mL) and 30% H 2 O 2 The reaction mixture was stirred at 0°C for 30 minutes and then heated to 55°C for another 8 hours. After TLC showed that the reaction was no longer proceeding, K 2 CO 3 The saturated aqueous phase was extracted with dichloromethane for three times. After the organic phases were combined, they were dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. After vacuum drying, 1.30 g of intermediate 21-4 was obtained as a colorless oily liquid with a yield of 87.3%.

[0195] Intermediate 21-4 was dissolved in 20 ml of dichloromethane, and 0.64 g of pyridine (8 mmol) and 1.9 g of p-toluenesulfonyl chloride (10 mmol) were added to the solution under an ice bath. The reaction was monitored by thin layer chromatography and the reaction was complete after stirring for 5 hours. 15 ml of water was added to the mixture, and stirring was continued for half an hour. The mixture was transferred to a separatory funnel, and the organic phase was extracted with dichloromethane and combined. The organic layer was washed with 0.1 N hydrochloric acid (15 mL), 5% sodium bicarbonate (15 mL) and water (15 mL). It was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and dried under vacuum to obtain 1.14 g of intermediate 21-5 as a white solid with a yield of 65.4%.

[0196] The above intermediate 21-5 (3.8 mmol), 0.81 g (5 mmol) N-phenylpiperazine and 0.69 g (5 mmol) anhydrous potassium carbonate were added to a 100 mL round-bottom flask. 40 mL acetonitrile was added to dissolve the solid, and the mixture was heated, stirred and refluxed for 12 hours. After the reaction was completed, the mixture was cooled to room temperature, the inorganic salts were filtered out, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, the acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, vacuum dried, and separated by silica gel column chromatography (eluent: dichloromethane: methanol: ammonia water = 10:1:0.5) to prepare and collect LY-3-6 to obtain 0.60 g of a white solid with a yield of 43.4%. ESI-MS m / z: 369.21 [M+H] + ; 1 HNMR (600 MHz, DMSO-d 6 )δ(ppm)7.22-7.17(m,2H),6.91(d,J=8.2Hz,2H),6.76(t,J=7.3Hz,1H),6.45(dd,J=8.2,1.4Hz,2H),5.92(s,2H),3.80(s,3H),3.1 0(t,J=4.9Hz,4H),2.52(d,J=2.4Hz,2H),2.48(d,J=5.9Hz,4H),2.33(t,J=7.4Hz,2H),1.55(q,J=7.6Hz,2H),1.46(q,J=7.8Hz,2H).

[0197] Example 22: Synthesis of 2-(4-(4-(7-methoxybenzo[d][1,3]dioxol-5-yl)butyl)piperazin-1-yl)pyrimidine (LY-3-7)

[0198] Referring to the method of compound LY-3-6 in Example 21, 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine in step [21-2] to prepare compound LY-3-7, and 0.54 g of yellow solid was obtained with a yield of 38.5%. ESI-MS m / z: 371.20 [M+H] + ; 1H NMR (600MHz, DMSO-d6) δ (ppm) 8.34 (d, J = 4.7Hz, 2H), 6.61 (t, J = 4.8Hz, 1H), 6.45 (d, J = 7.8Hz, 2H), 5.93 (s, 2H), 3.81 (s, 3H), 3.7 4-3.67(m,4H),2.50(d,J=1.7Hz,2H),2.38(t,J=5.1Hz,4H),2.31(t,J=7.4Hz,2H),1.56(p,J=7.5Hz,2H),1.45(p,J=7.5Hz,2H).

[0199] Example 23: Synthesis of 1-(4-(Benzo[d][1,3]dioxol-4-yl)butyl)-4-phenylpiperazine (LY-3-12)

[0200] Referring to the method of compound LY-3-6 in Example 21, benzo[d][1,3]dioxol-4-carboxaldehyde was used to replace 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde in step [21-1] to prepare compound LY-3-12, and 0.44 g of white solid was obtained with a yield of 34.6%. ESI-MS m / z: 339.20 [M+H] + ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)7.30-7.10(m,2H),6.91(d,J=8.3Hz,2H),6.80-6.73(m,3H),6.70(dd,J=6.6,2.5Hz,1H),5.97(s,2H),3.18- 3.02(m,4H),2.55(t,J=7.6Hz,2H),2.46(t,J=5.0Hz,4H),2.32(t,J=7.3Hz,2H),1.60(p,J=7.6Hz,2H),1.47(ddd,J=14.8,8.5,6.0Hz,2H).

[0201] Example 24: Synthesis of 2-(4-(4-(Benzo[d][1,3]diol-4-yl)butyl)piperazin-1-yl)pyrimidine (LY-3-13)

[0202] Referring to the method of compound LY-3-6 in Example 21, benzo[d][1,3]dioxol-4-carboxaldehyde was used to replace 7-methoxybenzo[d][1,3]dioxolane-5-carboxaldehyde in step [21-1], and 2-(piperazin-1-yl)pyrimidine was used to replace N-phenylpiperazine in step [21-2] to prepare compound LY-3-13, and 0.37 g of white solid was obtained with a yield of 28.7%. ESI-MSm / z: 341.19 [M+H]+ ; 1 H NMR(600MHz,DMSO-d6)δ(ppm)8.34(dd,J=4.7,1.3Hz,2H),6.76(dd,J=6.7,1.5Hz,2H),6.70(dt,J=6.5,2.0Hz,1H),6.60(td,J=4.7,1.6Hz,1H), 5.97(s,2H),3.74-3.67(m,4H),2.55(t,J=7.6Hz,2H),2.37(t,J=5.1Hz, 4H), 2.31 (t, J = 7.4Hz, 2H), 1.61 (q, J = 7.4Hz, 2H), 1.47 (p, J = 7.5Hz, 2H).

[0203] Example 25: Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-36)

[0204]

[0205] [25-1] Synthesis of tert-butyl 4-(3-methoxybenzylidene)piperidine-1-carboxylate (Intermediate 25-2)

[0206] Weigh 2.0 g (10 mmol) of 1-(bromomethyl)-3-methoxybenzene and triphenylphosphine (3.93 g, 15.0 mmol), place in a 250 ml round-bottom flask, add 50 ml of toluene as solvent, heat the reaction mixture to 115 ° C, and continue to react for 7 hours. Filter the reaction mixture, wash the collected solid with toluene (40 mL), and vacuum dry to obtain 4.04 g of intermediate 25-1, with a yield of 87.4%, in the form of a white powdery solid.

[0207] Intermediate 25-1 and 20mL of anhydrous THF were added to a 100mL three-necked flask equipped with a constant pressure dropping funnel. Under nitrogen protection, 12ml of 1M potassium tert-butoxide tetrahydrofuran solution (12mmol) was slowly added in an ice bath at 0°C, and the reaction mixture was stirred for 30 minutes. Keeping the ice bath condition, 10mL of anhydrous THF solution (2.0g, 10mmol) of tert-butyl 4-oxopiperidin-1-carboxylate was added dropwise in a constant pressure funnel. Stirring was continued at room temperature for 8h. Water was added to quench the reaction system under an ice bath. The organic phase was extracted with ethyl acetate 3 times, 30mL each time. After combining the organic phases, it was dried over anhydrous sodium sulfate, filtered through diatomaceous earth and concentrated under reduced pressure. After separation by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1), it was dried under vacuum to obtain 1.9g of intermediate 25-2 as a white solid with a yield of 71.6%. ESI-MS m / z:304.18[M+H] +; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.24(s,1H),7.11(dt,J=8.0,2.3Hz,1H),6.87(t,J=2.2Hz,1H),6.81(dt,J=7.9,2.6Hz,1H),6.16( d,J=1.3Hz,1H),3.75(s,3H),3.51(d,J=5.9Hz,2H),3.34(d,J=5.3Hz,2H),2.61-2.53(m,4H),1.42(s,9H).

[0208] [25-2] Synthesis of 4-(3-methoxybenzyl)piperidine (Intermediate 25-4)

[0209] At room temperature, 10% Pd / C (1.0 g, 1.0 mmol) was added to the methanol solution (40 mL) of the intermediate 25-2 obtained by the above reaction, and the reaction system was filled with hydrogen. Heat to 35 ° C and stir to react for 4 hours. The reaction mixture was filtered through diatomaceous earth, the filtrate was dissolved with ethyl acetate, and the organic layer was washed with water and saturated brine in turn. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and vacuum dried to obtain 1.55 g of the crude product of intermediate 25-3 with a yield of 81.5%. The intermediate 25-3 was dissolved in 20 ml of dichloromethane, and 20 ml of trifluoroacetic acid was slowly added at 0 ° C, and the reaction was stirred at room temperature for 20 hours. The solvent was spin-dried, the residue was dissolved in ethyl acetate, and the organic phase was extracted 3 times with a mixed solvent (dichloromethane: methanol = 10:1), 20 mL each time. After the organic phases were combined, they were dried over anhydrous sodium sulfate. The desiccant was filtered, the solvent was dried, and the intermediate 25-4 was prepared by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain 0.93 g of a white solid with a yield of 89.0%. ESI-MS m / z: 206.15 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 8.35 (s, 1H), 7.21 (t, J = 8.0Hz, 1H), 6.86-6.65 (m, 3H), 3.73 (s, 3H), 3.24 (d, J = 12.5Hz ,2H),2.81(h,J=9.9Hz,2H),2.50(s,2H),1.80(dqd,J=11.0,7.3,3.5Hz,1H),1.74-1.66(m,2H),1.37-1.26(m,2H).

[0210] [25-3] Synthesis of 6-chlorobenzo[d][1,3]dioxolanol (Intermediate 25-5)

[0211] Weigh 1.38g of benzo[d][1,3]dioxolane alcohol (10mmol) into a 100ml round-bottom flask, add 30ml of dichloromethane to dissolve, add 1.6g (12mmol) of N-chlorosuccinimide (NCS) under ice bath conditions, and continue stirring at room temperature for 6 hours. Remove the solvent in vacuo, separate by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1), and dry under vacuum to obtain 1.6g of white crystalline powder of intermediate 25-5, with a yield of 92.9%. ESI-MS m / z: 172.99 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)9.73(s,1H),6.94(s,1H),6.58(d,J=3.3Hz,1H),5.95(s,2H).

[0212] [25-4] Synthesis of 6-chlorobenzo[d][1,3]dioxolanol (Intermediate 25-6)

[0213] 1.6 g of intermediate 25-5 (9.3 mmol) and 1.66 g (12 mmol) of anhydrous potassium carbonate were placed in a 100 mL round-bottom flask, 40 mL of acetone was added as a solvent, and the mixture was stirred to dissolve. 1 g (22 mmol) of 1-bromo-2-chloroethane was added dropwise, and the reaction was stirred under reflux for 6 hours. After TLC detected that the reaction was no longer proceeding, the reaction solution was cooled to room temperature, solid potassium carbonate was filtered out, and the filter residue was washed with a small amount of acetone. The filtrate was concentrated, the residue was dissolved with ethyl acetate, and the organic layer was washed with water and saturated brine in turn. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and dried in vacuo to obtain 1.8 g of intermediate 25-6 as a white solid with a yield of 82.9%. ESI-MS m / z: 234.99 [M + H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.07(s,1H),6.98(s,1H),6.03(s,2H),4.29-4.23(m,2H),3.91(dd,J=5.9,4.3Hz,2H).

[0214] [25-5] Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-36)

[0215] 1.8 g of intermediate 25-6 (7.7 mmol), 0.93 g (4.54 mmol) of intermediate 25-4 and 1.04 g (7.5 mmol) of anhydrous potassium carbonate were added to a 100 mL round-bottom flask. 50 mL of acetonitrile was added to dissolve the solid, and the mixture was heated, stirred and refluxed for 8 hours. After the reaction was completed, the mixture was cooled to room temperature, the inorganic salts were filtered out, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, the acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain an eluate containing compound LY-3-36, which was dried under vacuum to obtain 0.77 g of a brown solid with a yield of 42.0%. ESI-MS m / z: 404.16 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.18(t,J=7.9Hz,1H),7.04(s,1H),6.96(s,1H),6.75-6.71(m,3H),6.01(s,2H),4.06(t,J=5.8Hz,2H),3.73(s,3H),2.93 (d,J=11.4Hz,2H),2.68(s,2H),2.45(d,J=6.9Hz,2H),2.10-1.94(m,2H),1.54(s,1H),1.50(d,J=11.7Hz,2H),1.23-1.17(m,2H). 13 C NMR(151MHz,DMSO)δ(ppm)159.64,149.54,147.37,142.41,141.67,129.54,121.73,115.12,113.0 3,111.53,109.98,102.23,98.27,89.92,68.52,57.17,55.32,54.11,42.81,40.54,37.43,32.11.

[0216] Example 26: Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxybenzyl)piperazine (LY-3-41)

[0217]

[0218] [26-1] Synthesis of 1-(3-methoxybenzyl)piperazine (Intermediate 26-2)

[0219] 2.0g 1-(bromomethyl)-3-methoxybenzene (10mmol), 2.78g tert-butyl piperazine-1-carboxylate (15mmol) and 2.07g anhydrous potassium carbonate (15mmol) were added to a 100mL round-bottom flask. 50mL acetonitrile was added to dissolve the solid, and heated, stirred and refluxed for 8 hours. After the reaction was completed, it was cooled to room temperature, filtered to remove inorganic salts, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated and dried under vacuum to obtain intermediate 26-1, which was a white powdery solid of 2.65g with a yield of 86.4%.

[0220] Dissolve the intermediate 26-1 in 20 ml of dichloromethane, and slowly add 20 ml of trifluoroacetic acid at 0°C, and stir the reaction at room temperature for 20 hours. The solvent was dried, and the residue was dissolved in dichloromethane. The organic phase was extracted 3 times with a mixed solvent (dichloromethane: methanol = 10:1), 20 mL each time. After the organic phases were combined, they were dried over anhydrous sodium sulfate. Filter the desiccant, dry the solvent, and prepare the intermediate 26-2 by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10:1:0.5) to obtain 1.37 g of white solid with a yield of 77.3%. ESI-MS m / z: 207.14 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 9.15 (s, 1H), 7.32 (t, J = 7.9Hz, 1H), 7.05-6.97 (m, 2H ),6.95(dd,J=8.4,2.6Hz,1H),3.93(s,2H),3.76(s,3H),3.26(s,4H),2.99(s,4H).

[0221] [26-2] Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxybenzyl)piperazine (LY-3-41)

[0222] Referring to the method of compound LY-3-36 in Example 25, 1-(3-methoxybenzyl)piperazine (intermediate 26-2) was used to replace 4-(3-methoxybenzyl)piperidine (intermediate 25-4) in step [25-5] to prepare compound LY-3-41 to obtain 1.52 g of yellow solid with a yield of 89.1%. ESI-MS m / z: 405.15 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.22(t,J=7.8Hz,1H),7.04(s,1H),6.96(s,1H),6.90-6.83(m,2H),6.81(dd,J=8.3,2.7Hz,1H),6.01( s,2H),4.07(t,J=5.7Hz,2H),3.73(m,3H),3.42(s,2H),2.68(t,J=5.7Hz,2H),2.62-2.51(m,4H),2.37(s,4H). 13 C NMR(151MHz,DMSO)δ(ppm)159.71,149.55,147.37,141.66,140.37,129.64,121.45,114 .68,113.01,112.75,109.98,102.23,98.25,68.52,62.43,56.92,55.39,53.58,53.10.

[0223] Example 27: Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxyphenyl)piperazine (LY-3-16)

[0224] Referring to the method of compound LY-3-36 in Example 25, 1-(3-methoxyphenyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine (intermediate 25-4) in step [25-5] to prepare compound LY-3-16 to obtain 1.3 g of yellow solid with a yield of 74.3%. ESI-MS m / z: 391.13 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.10(d,J=8.2Hz,1H),7.07(d,J=14.8Hz,1H),6.99(s,1H),6.51(dd,J=8.3,2.3Hz,1H),6.44(t,J=2.4Hz,1H),6.35(dd,J=8 .0,2.3Hz,1H),6.01(s,2H),4.12(t,J=5.7Hz,2H),3.71(s,3H),3.12(t,J=4.9Hz,4H),2.74(t,J=5.8Hz,2H),2.64(t,J=5.2Hz,4H). 13C NMR(151MHz,DMSO)δ(ppm)160.67,152.89,149.57,147.40,141.69,130.04,113.05,109 .99,108.46,104.57,102.24,101.89,98.29,68.63,56.95,55.38,55.31,53.57,48.65.

[0225] Example 28: Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-oxy)propyl)-4-(3-methoxybenzyl)piperidine (LY-3-35)

[0226]

[0227] [28-1] Synthesis of 3-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)propyl 4-methylbenzenesulfonate (Intermediate 28-2)

[0228] Referring to the synthesis of 6-chlorobenzo[d][1,3]dioxolane (Intermediate 26-6) in Example 25, 3-bromopropane-1-ol was used to replace 1-bromo-2-chloroethane in step [25-4] to prepare Intermediate 28-1 to obtain 0.8 g of a colorless oily liquid with a yield of 85.4%.

[0229] Intermediate 28-1 was dissolved in 20 ml of dichloromethane, and 0.8 g of pyridine (10.0 mmol) was added to the solution under an ice bath (0 ° C), and then 2.86 g of p-toluenesulfonyl chloride (15 mmol) was added. The reaction was monitored by thin layer chromatography. The reaction was completed after stirring for 5 hours. 20 ml of water was added to the mixture, and after stirring for half an hour, the mixture was transferred to a separatory funnel, and the organic phase was extracted with dichloromethane and combined, and the organic layer was washed with 0.1 N hydrochloric acid (20 mL), 5% sodium bicarbonate (20 mL) and water (25 mL). Dry with anhydrous sodium sulfate. Filter the desiccant, concentrate the solvent under reduced pressure, separate by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3:1), and obtain the eluate containing intermediate 28-2, which was dried under vacuum to obtain 0.9 g of a white powdery solid with a yield of 67.1%. ESI-MS m / z: 385.04 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.75(d,J=8.3Hz,2H),7.38(d,J=7.9Hz,2H),7.02(s,1H),6.83(s,1H),6.02(s ,2H),4.19(t,J=6.2Hz,2H),3.90(t,J=5.8Hz,2H),2.37(s,3H),2.00(h,J=6.1Hz,2H).

[0230] [28-2] Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-oxy)propyl)-4-(3-methoxybenzyl)piperidine (LY-3-35)

[0231] Referring to the synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)oxy)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-36) in Example 25, the intermediate 28-2 obtained in the previous step was used to replace the 6-chlorobenzo[d][1,3]dioxol (intermediate 25-6) in step [25-5] to prepare compound LY-3-35 to obtain 0.53 g of a light brown solid with a yield of 45.7%. ESI-MS m / z: 418.17 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.18(t,J=8.0Hz,1H),7.04(s,1H),6.94(s,1H),6.77-6.71(m,3H),6.01(s,2H),4.00(t,J=6.2Hz,2H),3.73(s,3H),2.94(s,2 H),2.51(q,J=1.9Hz,1H),2.47(d,J=6.7Hz,2H),2.14-1.92(m,2H),1.89(s,2H),1.57(d,J=13.3Hz,2H),1.25(dd,J=15.6,7.1Hz,2H). 13 C NMR(151MHz,DMSO)δ(ppm)159.67,149.53,147.40,142.29,141.68,129.58,121.72,115.11,113.13,1 11.60,109.97,102.24,98.31,68.40,55.39,55.33,54.69,53.42,49.05,42.63,37.24,31.52,26.22.

[0232] Example 29: Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-oxy)propyl)-4-(3-methoxybenzyl)piperazine (LY-3-46)

[0233] Referring to the method of compound LY-3-35 in Example 28, 1-(3-methoxybenzyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine to prepare compound LY-3-46, and 0.45 g of brown solid was obtained with a yield of 38.9%. ESI-MS m / z: 419.17 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)1H NMR (600MHz, DMSO) δ7.22(t,J=7.9Hz,1H),7.04(s,1H),6.94(s,1H),6.86(d,J=7.6Hz,2H),6.83-6.79(m,1H),6.01(s,2H ),4.00(t,J=6.2Hz,2H),3.74(s,3H),3.44(s,2H),3.36(m,2H),2.49-2.40(m,4H),2.40-2.10(m,4H),1.90-1.78(m,2H). 13 C NMR(151MHz,DMSO)δ(ppm)159.72,149.58,147.40,141.63,129.72,121.48,114.72,113.11,112.8 7,112.79,109.98,102.23,98.27,68.43,62.35,62.24,55.39,54.62,53.57,53.13,52.37,26.51.

[0234] Example 30: Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-oxy)propyl)-4-(3-methoxyphenyl)piperazine (LY-3-17)

[0235] Referring to the method of compound LY-3-35 in Example 28, 1-(3-methoxyphenyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine to prepare compound LY-3-17, and 0.47 g of yellow solid was obtained with a yield of 42.5%. ESI-MS m / z: 405.15 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.09(t,J=8.2Hz,1H),7.05(s,1H),6.96(s,1H),6.51(dd,J=8.4,2.3Hz,1H),6.43(t,J=2.3Hz,1H),6.35(dd,J=8.1,2.3Hz,1 H), 6.01 (s, 2H), 4.04 (t, J = 6.2Hz, 2H), 3.71 (s, 3H), 3.31 (s, 2H), 3.11 (t, J = 5.0Hz, 4H), 2.50 (d, J = 2.2Hz, 4H), 1.88 (p, J = 6.6Hz, 2H). 13 C NMR(151MHz,DMSO)δ(ppm)152.90,149.62,147.41,141.63,130.06,113.12,109.99,108.4 7,104.54,102.23,101.88,98.30,68.51,65.50,55.31,54.74,53.24,48.63,40.53,26.65.

[0236] Example 31: Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-47)

[0237]

[0238] [31-1] Synthesis of 2-(Benzo[d][1,3]dioxol-5-yl)ethanol (Intermediate 31-1)

[0239] Weigh 1.8 g of 2-(benzo[d][1,3]dioxol-5-yl)acetic acid (10 mmol), add 20 mL of anhydrous THF and place in a 100 mL three-necked flask. Under nitrogen protection, slowly add 4.8 ml of 2.5 M lithium aluminum tetrahydride in tetrahydrofuran solution (12 mmol) at 0 ° C in an ice bath, and stir the reaction mixture for 30 minutes. Stir the reaction for 3 hours under ice bath conditions. TLC monitors the reaction progress until the reaction is complete. Slowly add H 2 O (0.5 mL), 15% aqueous NaOH (0.5 mL) and H 2 O (1.5 mL) to quench the reaction. Filter the solution through celite. Pour the solution into ethyl acetate (30 mL). Wash the organic layer with saturated brine. Dry the organic layer over anhydrous sodium sulfate, filter and concentrate under reduced pressure. Dry under vacuum to obtain 1.86 g of intermediate 31-1 as a white solid with a yield of 93.2%. ESI-MS m / z: 167.06 [M+H] + ; 1 H NMR (600 MHz, DMSO-d6 )δ(ppm)6.91-6.73(m,2H),6.66(dd,J=8.0,1.6Hz,1H),5.95(s,2H),4.59(t,J=5.2Hz,1H),3.54(td,J=7.1,5.2Hz,2H),2.63(t,J=7.1Hz,2H).

[0240] [31-2] Synthesis of 2-(6-chlorobenzo[d][1,3]dihydroxy-5-yl)ethyl-4-methylbenzenesulfonate (Intermediate 31-3)

[0241] 1.86g of intermediate 31-1 (9.32mmol) was dissolved in 30ml of dichloromethane in a 100ml round-bottom flask, and 1.6g (12mmol) of N-chlorosuccinimide (NCS) was added under ice bath conditions, and stirring was continued at room temperature for 6 hours. The solvent was removed in vacuo, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and dried under vacuum to obtain 1.57g of white powder of intermediate 31-2, with a yield of 84.4%.

[0242] The intermediate 31-2 was dissolved in 25 ml of dichloromethane, and 0.8 g of pyridine (10.0 mmol) was added to the solution under an ice bath (0 ° C), and then 2.86 g of p-toluenesulfonyl chloride (15 mmol) was added. The reaction was monitored by thin layer chromatography. After stirring for 5 hours, it was completely completed. 20 ml of water was added to the mixture, and after stirring for half an hour, the mixture was transferred to a separatory funnel, and the organic phase was extracted with dichloromethane and combined, and the organic layer was washed with 0.1N hydrochloric acid (20 mL), 5% sodium bicarbonate (20 mL) and water (25 mL). Dry with anhydrous sodium sulfate. Filter the desiccant, concentrate the solvent under reduced pressure, separate it by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2: 1), and obtain the eluate containing the intermediate 31-3, which was dried under vacuum to obtain 1.88 g of white powder of the intermediate 31-3 with a yield of 67.5%. ESI-MS m / z: 355.03 [M + H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.73-7.57(m,2H),7.41(d,J=8.1Hz,2H),6.96(s,1H),6.83(s,1H ),6.05(s,2H),4.19(t,J=6.5Hz,2H),2.90(t,J=6.5Hz,2H),2.41(s,3H).

[0243] [31-3] Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-47)

[0244] 1.88g of intermediate 31-3 (5.7mmol), 1.4g (7mmol) of 4-(3-methoxybenzyl)piperidine and 1.04g (7.5mmol) of anhydrous potassium carbonate were added to a 100mL round-bottom flask. 50mL of acetonitrile was added to dissolve the solid, and the mixture was heated, stirred and refluxed for 20 hours. After the reaction was completed, the mixture was cooled to room temperature, the inorganic salts were filtered out, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, the acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain an eluate containing compound LY-3-47, which was dried under vacuum to obtain 1.1g of a yellow solid of compound LY-3-47 with a yield of 49.9%. ESI-MS m / z: 388.16 [M+H] + ; 1 H NMR (600MHz, DMSO-d6) δ (ppm) 7.11 (t, J = 7.8 Hz, 1H), 6.93 (s, 1H), 6.87 (s, 1H), 6.69-6.63 (m, 3H), 5.95 (s, 2H), 3.66 (s, 3H), 2.85 (s,2H),2.67(t,J=7.4Hz,2H),2.39(t,J=8.6Hz,4H),2.00-1.80(m,2H),1.48(d,J=13.1Hz,2H),1.23(s,1H),1.14-1.07(m,2H). 13 C NMR(151MHz,DMSO)δ(ppm)159.65,146.98,146.91,142.41,129.55,126.24,124.60,121.74,11 5.13,111.55,110.81,109.80,102.20,55.59,55.38,53.49,42.78,40.53,37.56,34.58,32.03.

[0245] Example 32: Synthesis of 1-(2-(6-chlorobenzo[d][1,3]dioxol-5-yl)ethyl)-4-(3-methoxybenzyl)piperazine (LY-3-43)

[0246] Referring to the method of compound LY-3-47 in Example 31, 1-(3-methoxybenzyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine in step [31-3] to prepare compound LY-3-43 to obtain 1.0 g of brown solid with a yield of 47.5%. ESI-MS m / z: 389.16 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm).7.22(t,J=7.8Hz,1H),7.00(s,1H),6.95(s,1H),6.88-6.84(m,2H),6.80(dd,J=8.3,2.5Hz,1H), 6.02(s,2H),3.73(s,3H),3.42(s,2H),3.33(s,2H),2.75-2.71(m,2H),2.44(t,J=7.8Hz,4H),2.37(s,4H). 13 CNMR(151MHz,DMSO)δ(ppm)159.71,146.97,146.88,140.44,132.13,131.29,129.63,124 .59,121.41,114.64,112.74,110.84,109.78,102.19,62.44,58.33,55.39,53.10,30.62.

[0247] Example 33: Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-yl)propyl)-4-(3-methoxybenzyl)piperidine (LY-4-28)

[0248]

[0249] [33-1] Synthesis of 3-(Benzo[d][1,3]dihydroxy-5-yl)propan-1-ol (Intermediate 33-1)

[0250] Referring to the synthesis of 2-(benzo[d][1,3]diol-5-yl)ethanol (Intermediate 31-1) in Example 31, 3-(benzo[d][1,3]dihydroxy-5-yl)propionic acid was used to replace 2-(benzo[d][1,3]diol-5-yl)acetic acid in step [31-1] to prepare Intermediate 33-1, and 1.6 g of a white solid was obtained with a yield of 89.4%. ESI-MS m / z: 181.08 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)6.90-6.69(m,2H),6.64(dd,J=7.8,1.7Hz,1H),5.95(s,2H),4.44 (t,J=5.2Hz,1H),3.41-3.38(m,2H),2.54-2.50(m,2H),1.70-1.63(m,2H).

[0251] [33-2] Synthesis of 3-(6-chlorobenzo[d][1,3]dioxol-5-yl)propyl 4-methylbenzenesulfonate (Intermediate 33-3)

[0252] Referring to the synthesis of 2-(6-chlorobenzo[d][1,3]dihydroxy-5-yl)ethyl-4-methylbenzenesulfonate (Intermediate 31-3) in Example 31, 3-(benzo[d][1,3]dihydroxy-5-yl)propan-1-ol (Intermediate 33-1) obtained in the previous step was used to replace 2-(benzo[d][1,3]dihydroxy-5-yl)ethanol (Intermediate 31-1) in step [31-2] to prepare Intermediate 33-3, and 1.92 g of a white solid was obtained with a yield of 58.4%. ESI-MS m / z: 369.05 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)7.86-7.74(m,2H),7.48(d,J=8.0Hz,2H),6.98(s,1H),6.76(s,1H),6.04 (s,2H),4.05(t,J=6.2Hz,2H),2.61-2.55(m,2H),2.43(s,3H),1.86-1.79(m,2H).

[0253] [33-3] Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-yl)propyl)-4-(3-methoxybenzyl)piperidine (LY-4-28)

[0254] Referring to the synthesis of 1-(2-(6-chlorobenzo[d][1,3]diol-5-yl)ethyl)-4-(3-methoxybenzyl)piperidine (LY-3-47) in Example 31, 3-(6-chlorobenzo[d][1,3]diol-5-yl)propyl 4-methylbenzenesulfonate (Intermediate 33-3) obtained in the previous step was used to replace 2-(6-chlorobenzo[d][1,3]dihydroxy-5-yl)ethyl-4-methylbenzenesulfonate (Intermediate 31-3) in step [31-3] to prepare compound LY-4-28 to obtain 0.86 g of a white solid with a yield of 41.3%. ESI-MSm / z: 402.18[M+H] + ; 1H NMR(600MHz,DMSO-d6)δ(ppm).7.17(t,J=7.9Hz,1H),6.98(s,1H),6.89(s,1H), 6.77-6.67(m,3H),6.02(s,2H),3.72(s,3H),2.83-2.77(m,2H),2.57(t,J=7.7H z,2H),2.45(d,J=7.2Hz,2H),2.23(t,J=7.1Hz,2H),1.77(t,J=11.5Hz,2H),1.6 3(p,J=7.3Hz,2H),1.55-1.50(m,2H),1.30(s,1H),1.18(td,J=12.1,3.7Hz,2H). 13 C NMR(151MHz,DMSO)δ(ppm)δ159.63,146.96,146.68,142.48,133.06,129.50,124.41,121.71,115.1 1,111.47,110.45,109.79,102.14,57.78,55.29,53.75,42.95,37.89,37.83,32.27,31.07,27.38.

[0255] Example 34: Synthesis of 1-(3-(6-chlorobenzo[d][1,3]dioxol-5-yl)propyl)-4-(3-methoxybenzyl)piperazine (LY-4-29)

[0256] Referring to the method of compound LY-4-28 in Example 33, 1-(3-methoxybenzyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine in step [33-3] to prepare compound LY-4-29, and 0.62 g of red-brown solid was obtained with a yield of 29.8%. ESI-MS m / z: 403.17 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm).7.22(t,J=7.8Hz,1H),6.99(s,1H),6.90(s,1H),6.87-6.84(m,2H),6.82-6.79(m,1H),6.02(s,2H),3.73(s, 3H),3.41(s,2H),3.35(s,2H),2.58(dd,J=8.8,6.7Hz,2H),2.36(s,6H),2.26(t,J=7.1Hz,2H),1.64(h,J=6.4Hz,2H). 13C NMR(151MHz,DMSO)δ(ppm)159.71,146.97,146.70,140.44,133.03,129.60,124.41,121.42,114.6 6,112.70,110.47,109.80,102.15,62.53,57.47,55.36,53.19(d,J=2.9Hz),51.53,31.02,27.23.

[0257] Example 35: Synthesis of 1-(4-(6-chlorobenzo[d][1,3]dioxol-5-yl)butyl)-4-(3-methoxybenzyl)piperidine (LY-4-30)

[0258]

[0259] [35-1] Synthesis of 4-(6-chlorobenzo[d][1,3]dihydroxy-5-yl)butan-1-ol (Intermediate 35-3)

[0260] Weigh 2.4 g (15 mmol) of diethyl malonate in a dry 100 mL three-necked flask and add 10 mL of anhydrous tetrahydrofuran to dissolve. Place the flask in an ice bath and cool to 0 ° C under nitrogen protection. Under a nitrogen atmosphere, slowly add 0.36 g of sodium hydride (15 mmol) to the reaction flask. Dissolve 3.54 g of 2-(6-chlorobenzo[d][1,3]dihydroxy-5-yl)ethyl-4-methylbenzenesulfonate (10 mmol) in 10 mL of anhydrous THF to form a solution, and slowly add it dropwise to the reaction mixture under a nitrogen atmosphere while keeping the ice bath cool. Stir the reaction mixture in an ice bath for 30 minutes and then move to 45 ° C and continue stirring under heating conditions. After the reaction is completed, add water to terminate the reaction. After evaporating the solvent under reduced pressure, extract the organic phase 3 times with ethyl acetate, 20 mL each time. After the organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 3.1 g of white solid intermediate 35-1 with a yield of 90.0%.

[0261] The intermediate 35-1 (9 mmol) obtained in the previous step and 0.64 g of lithium chloride (15 mmol) were added to a 100 ml round-bottom flask, and the mixture was dissolved with 30 ml of anhydrous DMSO, stirred at 150 ° C for 20 hours, and then cooled to room temperature. The mixture was distributed between ethyl acetate (50 mL) and water (50 ml), and the organic phase was extracted with ethyl acetate 3 times, 20 mL each time. The organic phases were combined, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 1.8 g of a white solid of intermediate 35-2, with a yield of 74.0%.

[0262] Add 20 mL of anhydrous THF to the intermediate 35-2 and place in a 100 mL three-necked flask. Under nitrogen protection, slowly add 3.2 ml of 2.5 M lithium aluminum tetrahydride tetrahydrofuran solution (8 mmol) at 0 °C in an ice bath, and stir the reaction mixture for 30 minutes. Stir the reaction for 3 hours under ice bath conditions. TLC monitors the reaction progress until the reaction is complete. Slowly add H 2 O (0.5 mL), 15% aqueous NaOH (0.56 mL) and H 2 O (1.5 mL) to quench the reaction. Filter the solution through diatomaceous earth. Pour the solution into ethyl acetate (30 mL). Wash the organic layer with saturated brine. Dry the organic layer over anhydrous sodium sulfate, filter and concentrate under reduced pressure to obtain 1.31 g of intermediate 35-3 as a white solid with a yield of 86.5%. ESI-MS m / z: 229.06 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6 )δ(ppm)6.98(s,1H),6.67(t,J=0.9Hz,1H),6.02(s,2H),3.89(td,J=6.8,5.8Hz,2H ),2.75(td,J=7.7,0.9Hz,2H),1.81-1.71(m,2H),1.67(ttd,J=8.1,6.7,1.2Hz,2H).

[0263] [35-2] Synthesis of 1-(4-(6-chlorobenzo[d][1,3]dioxol-5-yl)butyl)-4-(3-methoxybenzyl)piperidine (LY-4-30)

[0264] The intermediate 35-3 was dissolved in 25 ml of dichloromethane, and 0.8 g of pyridine (10.0 mmol) was added to the solution under an ice bath (0 ° C), and then 2.86 g of p-toluenesulfonyl chloride (15 mmol) was added. The reaction was monitored by thin layer chromatography. After stirring for 10 hours, it was completely completed. 20 ml of water was added to the mixture, and stirring was continued for half an hour. The mixture was transferred to a separatory funnel, and the organic phase was extracted with dichloromethane and combined. The organic layer was washed with 0.1N hydrochloric acid (20 mL), 5% sodium bicarbonate (20 mL) and water (25 mL). Dry with anhydrous sodium sulfate. Filter the desiccant, concentrate the solvent under reduced pressure, separate it by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1: 1), and obtain the eluate containing the intermediate 35-4, which was dried under vacuum to obtain 1.44 g of white powder of the intermediate 35-4, with a yield of 65.5%.

[0265] 1.44 g of intermediate 35-4 (3.77 mmol), 1.4 g (7 mmol) of 4-(3-methoxybenzyl)piperidine and 1.04 g (7.5 mmol) of anhydrous potassium carbonate were added to a 100 mL round-bottom flask. 50 mL of acetonitrile was added to dissolve the solid, and the mixture was heated, stirred and refluxed for 30 hours. After the reaction was completed, the mixture was cooled to room temperature, the inorganic salts were filtered out, and the filter residue was washed with a small amount of acetonitrile. The filtrate was combined, the acetonitrile was removed by rotary evaporation, and the residue was dissolved in ethyl acetate. The organic phase was washed with water and saturated brine in turn, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (dichloromethane: methanol: ammonia water = 10: 1: 0.5) to obtain an eluate containing compound LY-4-30, which was dried under vacuum to obtain 0.83 g of a yellow solid with a yield of 52.9%. ESI-MS m / z: 416.19 [M+H] + ; 1 H NMR (151MHz, DMSO) δ (ppm) 7.19 (t, J = 8.0 Hz, 1H), 7.01 (s, 1H), 6.93 (s, 1H), 6.78-6.71 (m, 3H), 6.03 (s, 2H), 3.73 (s, 3H), 3.29 (s, 2H), 3 .05(s,1H),2.59(t,J=7.4Hz,2H),2.47(d,J=6.8Hz,2H),1.61(d,J=12.7Hz,4H),1.55-1.43(m,4H),1.30(s,2H),1.24(d,J=9.4Hz,2H). 13 C NMR(151MHz,DMSO)δ(ppm)159.68,147.01,146.77,132.86,129.64,124.42,121.74, 115.15,111.67,110.48,109.85,102.19,55.35,40.53,34.59,32.79,30.18,27.54.

[0266] Example 36: Synthesis of 1-(4-(6-chlorobenzo[d][1,3]dioxol-5-yl)butyl)-4-(3-methoxybenzyl)piperazine (LY-4-31)

[0267] Referring to the method of compound LY-4-30 in Example 35, 1-(3-methoxybenzyl)piperazine was used to replace 4-(3-methoxybenzyl)piperidine in step [33-3] to prepare compound LY-4-31, and a brown solid of 0.78 g was obtained with a yield of 49.8%. ESI-MS m / z: 417.19 [M+H] + ; 1 H NMR (600 MHz, DMSO-d 6)δ(ppm)7.22(t,J=7.9Hz,1H),7.00(s,1H),6.91(s,1H),6.88-6.83(m,2H),6.83-6.79(m,1H),6.02(s,2H),3.73(s,3H),3. 43(s,2H),3.37(s,2H),2.58(t,J=7.4Hz,2H),2.51(p,J=1.8Hz,2H),2.36(s,6H),1.50(q,J=7.6Hz,2H),1.48-1.41(m,2H).

[0268] 13 C NMR(151MHz,DMSO)δ(ppm)159.71,146.99,146.71,140.19,133.09,129.65,128.70,124.40,121.48 ,114.73,112.80,110.43,109.82,102.16,62.33,57.72,55.39,52.99,52.72,32.94,27.79,25.97.

[0269] [Biological Activity Test Example 1]

[0270] The radioligand binding assay was used to test the binding of the compounds of the present invention to 5-hydroxytryptamine transporter (SERT) and 5-HT 1A The affinity of the receptor. The experimental methods and results are as follows:

[0271] 1. Materials and Reagents

[0272] Table 1 Materials and reagents used in radioligand binding experiments

[0273]

[0274]

[0275] 2. Operation method

[0276] (1) Solution preparation

[0277] Assay buffer: 50 mM Tris-HCl pH 7.4, 5 mM KCl, 120 mM NaCl, stored at 4°C.

[0278] Elution buffer: 50 mM Tris-HCl pH 7.4, 154 mM NaCl, stored at 4°C.

[0279] 0.5% PEI solution: add 0.5 mL PEI to 100 mL double distilled water and store at 4°C.

[0280] (2) 5-hydroxytryptamine transporter (SERT) radioligand binding assay

[0281] ① Add 5 μL of DMSO solution of the test compound (the final DMSO concentration is 1%) and 95 μL of test buffer into a 96-well plate.

[0282] ② Add 2 μL of 5-HT transporter protein and 298 μL of test buffer to each well.

[0283] ③ Add 100 μL [ 3 H]-imipramine (final radioligand concentration was 2 nM) and incubated at 27°C for 0.5 h.

[0284] ④ Pre-incubate the UNIFILTER-96GF / B filter plate with 0.5% PEI solution for 1 hour.

[0285] ⑤Wash each well of the UNIFILTER-96GF / B filter plate twice with 1 mL of elution buffer, transfer the protein mixture to the UNIFILTER-96GF / B filter plate, and wash 4 times.

[0286] ⑥Incubate at 55℃ for 10 minutes.

[0287] ⑦ Add 40 μL ULTIMA GOLD scintillation fluid to each well and read CPM using Microbeta-2.

[0288] (3) 5-HT 1A Receptor Radioligand Binding Assay Test

[0289] ① Add 5 μL of DMSO solution of the test compound (the final DMSO concentration is 1%) and 95 μL of test buffer into a 96-well plate.

[0290] ②Add 1.5 μL human 5-HT to each well 1A Cell membrane protein and 298.5 μL of assay buffer.

[0291] ③ Add 100 μL [ 3 H]-8-OH-DPAT (final radioligand concentration was 0.5 nM), and incubated at 27°C for 1 h.

[0292] ④ Pre-incubate the UNIFILTER-96GF / B filter plate with 0.5% PEI solution for 1 hour.

[0293] ⑤Wash each well of the UNIFILTER-96GF / B filter plate twice with 1 mL of elution buffer, transfer the protein mixture to the UNIFILTER-96GF / B filter plate, and wash 4 times.

[0294] ⑥Incubate at 55℃ for 10 minutes.

[0295] ⑦ Add 40 μL ULTIMA GOLD scintillation fluid to each well and read CPM using Microbeta-2.

[0296] (4) Data analysis

[0297] ①% inhibitory activity (Activity) was calculated using the following formula:

[0298] %Activity=(Signal cmpd -Signal Ave_VC ) / (Signal Ave_PC -Signal Ave_VC )×100

[0299] ②IC of the compound 50 And the dose-effect curve:

[0300] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))

[0301] X:log of agonist concentration; Y:%Activity.

[0302] 3. Experimental results

[0303] Table 2 The compounds of the present invention interact with 5-HT transporter (SERT) and 5-HT 1A Receptor affinity a

[0304]

[0305]

[0306] The compounds of the present invention and the positive reference compounds have an effect on the 5-hydroxytryptamine transporter (SERT) and 5-HT 1A The results of the affinity of the receptors are shown in Table 2. The experimental results show that the compounds of the present invention have a strong affinity for 5-HT 1A The compounds show high affinity for 5-HT receptors, and some of the compounds also show high affinity for 5-HT transporter (SERT), and are expected to be dual-target antidepressant drugs. SAR analysis shows that the compounds with the structure of formula I-1 described in the first aspect of the present invention show high dual binding to 5-HT in in vitro assays. 1A R / SERT activity, especially the compound LY-3-35 (Ki (5HT 1A)=2.72nM; Ki(SERT)=8.85nM), LY-4-31(Ki(5-HT 1A )=0.7nM;Ki(SERT)=10.33nM). In addition, compounds LY-3-17, LY-3-12 and LY-3-46 had an effect on 5-HT 1A The receptor has good affinity and its application in anti-anxiety and anti-depression is promising.

[0307] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A compound of formula I, a pharmaceutically acceptable salt, an isotope-labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a cocrystal thereof, in: X is selected from C 1-6 Alkylene, -NH-, -O-(CH 2 ) m -, -C(=O)-, CH(OH)-, -CH 2 NH-, CH 2 C(=O)-, -NHC(=O)-, -OC(=O)- and -CH=CHC(=O), wherein m is 0, 1, 2, 3, 4, 5 or 6; Y is N or CH; R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Alkylamino; n is 0, 1, 2, 3 or 4; Ar 1 for Where R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Alkylamino.

2. The compound according to claim 1, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal, wherein the compound has a structure shown in Formula I-1, Formula I-2 or Formula I-3, Where X, Y, R 1 , n is defined as in claim 1.

3. The compound according to claim 1 or 2, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal, wherein X is selected from C 1-4 Alkylene, -NH-, -O-(CH 2 ) m -, -C(=O)-, CH(OH)-, -CH 2 NH-、CH 2 C(═O)-, -NHC(═O)-, -OC(═O)-, and -CH═CHC(═O), wherein m is 0, 1, 2, 3, or 4; Preferably, X is selected from C 1-4 Alkylene, -O-(CH 2 ) m - and -CH=CHC(=O), wherein m is 0, 1, 2, 3 or 4; Preferably, X is selected from -O-CH 2 -, -O-(CH 2 ) 2 -, -O-(CH 2 ) 3 -, -O-(CH 2 ) 4 -, -CH=CHC(=O)-, -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -(CH 2 ) 4 -, -CH 2 CH 2 CH(CH 3 )-, -CH 2 CH(CH 3 )CH 2 -, and -CH(CH 3 )CH 2 CH 2 -; Preferably, X is selected from -O-(CH 2 ) 4 -、-O-(CH 2 ) 2 -、-O-(CH 2 ) 3 -、-CH=CHC(=O)-、-CH 2 -、-CH 2 CH 2 CH(CH 3 )-、-(CH 2 ) 3 -、-(CH 2 ) 4 - and - (CH 2 ) 2 -.

4. The compound according to any one of claims 1 to 3, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal, wherein R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Alkylamino; Preferably, R 1 Selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl and C 1-4 Alkoxy; Preferably, R 1 Selected from H, D, F, Cl, Br, I, C 1-4 Alkyl and C 1-4 Alkoxy; Preferably, R 1 is selected from H, D, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, n-butoxy; Preferably, R 1 Selected from H, D, F, Cl, Br, I, methoxy, ethoxy, n-propoxy, n-butoxy; Preferably, R 1 is selected from the group consisting of H, D, F, Cl, Br, I and methoxy; Preferably, R 1 is selected from H, F, Cl, Br, I and methoxy; Preferably, R 1 Selected from H, Cl and methoxy.

5. The compound according to any one of claims 1 to 4, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal, wherein n is 0, 1, 2 or 3; Preferably, n is 0, 1 or 2; Preferably, n is 0 or 1.

6. The compound according to any one of claims 1 to 5, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal, in: R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl, deuterated C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Alkylamino; Preferably, R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, -OH, -NH 2 、-NO 2 、-CN、C 1-4 Alkyl and C 1-4 Alkoxy; Preferably, R 2 , R 3 Each independently selected from H, D, F, Cl, Br, I, C 1-4 Alkyl and C 1-4 Alkoxy; Preferably, R 2 , R 3 Each is independently selected from H, D, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, n-butoxy; Preferably, R 2 , R 3 Each is independently selected from H, D, F, Cl, Br, I, methoxy, ethoxy, n-propoxy, n-butoxy; Preferably, R 2 , R 3 Each is independently selected from H, D, F, Cl, Br, I and methoxy; Preferably, R 2 , R 3 Each independently selected from H, F, Cl, Br, I and methoxy; Preferably, R 2 , R 3 are each independently selected from H and methoxy; Preferably, R 2 For H, R 3 It is a methoxy group.

7. The compound according to any one of claims 1 to 6, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal, wherein Ar 1 for 8. The compound according to any one of claims 1 to 7, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or co-crystal, wherein the compound is selected from:

9. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 8, a pharmaceutically acceptable salt, an isotope-labeled compound, a racemate, an enantiomer, a solvate, a hydrate, a crystal form or a cocrystal thereof, and one or more pharmaceutically acceptable carriers and / or excipients.

10. Use of the compound according to any one of claims 1 to 8, its pharmaceutically acceptable salt, isotope-labeled compound, racemate, enantiomer, solvate, hydrate, crystal form or cocrystal, or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating and / or preventing a disease or condition in a subject, wherein the disease or condition is related to 5-HT 1A Receptor and / or 5-HT transporter (SERT) related diseases; Preferably, the disease or condition is selected from cancer, pain, nervous system disease, immune system disease and any combination thereof; Preferably, the disease or condition is selected from hypertension, attention deficit / hyperactivity disorder (ADHD), pain, panic disorder, opioid withdrawal symptoms, benzodiazepines drug withdrawal symptoms, alcohol withdrawal symptoms, neurological disorders, and any combination thereof; Preferably, the neurological disease is selected from depression, bipolar disorder, anxiety, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), schizophrenia, generalized anxiety disorder, phobia, panic disorder, eating disorders, attention deficit hyperactivity disorder (ADHD), borderline personality disorder, dissociative identity disorder, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), epilepsy, cerebrovascular disease, cerebral palsy, neuropathic pain, chronic fatigue syndrome, sleep disorders, movement disorders and any combination thereof.